Acadia Healthcare (ACHC) 10-K 27 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2017	Feb. 27, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	ACHC
Entity Registrant Name	Acadia Healthcare Company, Inc.
Entity Central Index Key	1,520,697
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		87,950,965
Entity Public Float			$ 3.9

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 67,290	$ 57,063
Accounts receivable, net of allowance for doubtful accounts of $39,803 and $38,916, respectively	296,925	263,327
Other current assets	107,335	107,537
Total current assets	471,550	427,927
Property and equipment:
Land	450,342	411,331
Building and improvements	2,370,918	2,031,819
Equipment	400,596	318,020
Construction in progress	173,693	157,114
Less accumulated depreciation	(347,419)	(214,589)
Property and equipment, net	3,048,130	2,703,695
Goodwill	2,751,174	2,681,188
Intangible assets, net	87,348	83,310
Deferred tax assets - noncurrent	3,731	3,780
Derivative instruments	12,997	73,509
Other assets	49,572	51,317
Total assets	6,424,502	6,024,726
Current liabilities:
Current portion of long-term debt	34,830	34,805
Accounts payable	102,299	80,034
Accrued salaries and benefits	99,047	105,068
Other accrued liabilities	141,213	122,958
Total current liabilities	377,389	342,865
Long-term debt	3,205,058	3,253,004
Deferred tax liabilities - noncurrent	80,333	78,520
Other liabilities	166,434	164,859
Total liabilities	3,829,214	3,839,248
Redeemable noncontrolling interests	22,417	17,754
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 shares authorized; 87,060,114 and 86,688,199 issued and outstanding as of December 31, 2017 and 2016, respectively	871	867
Additional paid-in capital	2,517,545	2,496,288
Accumulated other comprehensive loss	(374,118)	(549,570)
Retained earnings	428,573	220,139
Total equity	2,572,871	2,167,724
Total liabilities and equity	$ 6,424,502	$ 6,024,726

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Receivable, allowance for doubtful accounts	$ 39,803	$ 38,916
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	87,060,114	86,688,199
Common stock, shares outstanding	87,060,114	86,688,199

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenue before provision for doubtful accounts	$ 724,512	$ 716,714	$ 715,896	$ 679,194	$ 702,888	$ 734,665	$ 756,548	$ 616,813	$ 2,877,234	$ 2,852,823	$ 1,829,619
Provision for doubtful accounts									(40,918)	(41,909)	(35,127)
Revenue									2,836,316	2,810,914	1,794,492
Salaries, wages and benefits (including equity-based compensation expense of $23,467, $28,345 and $20,472, respectively)									1,536,160	1,541,854	973,732
Professional fees									196,223	185,486	116,463
Supplies									114,439	117,425	80,663
Rents and leases									76,775	73,348	32,528
Other operating expenses									331,827	312,556	206,746
Depreciation and amortization									143,010	135,103	63,550
Interest expense, net									176,007	181,325	106,742
Debt extinguishment costs									810	4,253	10,818
Loss on divestiture										178,809
(Gain) loss on foreign currency derivatives										(523)	1,926
Transaction-related expenses									24,267	48,323	36,571
Total expenses									2,599,518	2,777,959	1,629,739
Income from continuing operations before income taxes	60,639	61,459	66,216	48,484	42,438	(115,814)	73,852	32,479	236,798	32,955	164,753
Provision for income taxes									37,209	28,779	53,388
Income (loss) from continuing operations									199,589	4,176	111,365
Income from discontinued operations, net of income taxes											111
Net income									199,589	4,176	111,476
Net loss attributable to noncontrolling interests									246	1,967	1,078
Net income attributable to Acadia Healthcare Company, Inc.	$ 69,629	$ 45,618	$ 49,630	$ 34,958	$ 41,818	$ (117,808)	$ 56,445	$ 25,688	$ 199,835	$ 6,143	$ 112,554
Basic earnings attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations									$ 2.30	$ 0.07	$ 1.65
Income from discontinued operations									0	0	0
Net income	$ 0.80	$ 0.52	$ 0.57	$ 0.40	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	2.30	0.07	1.65
Diluted earnings attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations									2.30	0.07	1.64
Income from discontinued operations									0	0	0
Net income	$ 0.80	$ 0.52	$ 0.57	$ 0.40	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	$ 2.30	$ 0.07	$ 1.64
Weighted-average shares outstanding:
Basic									86,948	85,701	68,085
Diluted									87,060	85,972	68,391

Consolidated Statements of Inc5

Consolidated Statements of Income (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Equity-based compensation expense	$ 23,467	$ 28,345	$ 20,472

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 199,589	$ 4,176	$ 111,476
Other comprehensive loss:
Foreign currency translation gain (loss)	207,341	(477,772)	(40,103)
(Loss) gain on derivative instruments, net of tax of $(22.9) million, $29.1 million and $0, respectively	(33,431)	40,598
Pension liability adjustment, net of tax of $0.4 million	1,542	(7,749)	3,826
Other comprehensive gain (loss)	175,452	(444,923)	(36,277)
Comprehensive income (loss)	375,041	(440,747)	75,199
Comprehensive loss attributable to noncontrolling interests	246	1,967	1,078
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$ 375,287	$ (438,780)	$ 76,277

Consolidated Statements of Com7

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
(Loss) gain on derivative instruments, tax	$ (22.9)	$ 29.1	$ 0
Pension liability adjustment, tax	$ 0.4	$ (1.3)	$ 0.9

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Other Comprehensive Loss [Member]	Earnings (Accumulated Deficit) [Member]
Balance at Dec. 31, 2014	$ 880,965	$ 592	$ 847,301	$ (68,370)	$ 101,442
Balance, shares at Dec. 31, 2014		59,212,000
Common stock issued under stock incentive plans	1,815	$ 4	1,811
Common stock issued under stock incentive plans, shares		384,000
Common stock withheld for minimum statutory taxes	(9,577)		(9,577)
Equity-based compensation expense	20,472		20,472
Excess tax benefit from equity awards	309		309
Issuance of common stock, net	711,517	$ 111	711,406
Issuance of common stock, net, shares		11,150,000
Other comprehensive gain (loss)	(36,277)			(36,277)
Other	1,250		1,250
Net income attributable to Acadia Healthcare Company, Inc. stockholders	112,554				112,554
Balance at Dec. 31, 2015	1,683,028	$ 707	1,572,972	(104,647)	213,996
Balance, shares at Dec. 31, 2015		70,746,000
Common stock issued under stock incentive plans	$ 1,384	$ 5	1,379
Common stock issued under stock incentive plans, shares	57,397	408,000
Common stock withheld for minimum statutory taxes	$ (10,230)		(10,230)
Equity-based compensation expense	28,345		28,345
Issuance of common stock, net	901,979	$ 155	901,824
Issuance of common stock, net, shares		15,534,000
Other comprehensive gain (loss)	(444,923)			(444,923)
Other	1,998		1,998
Net income attributable to Acadia Healthcare Company, Inc. stockholders	6,143				6,143
Balance at Dec. 31, 2016	$ 2,167,724	$ 867	2,496,288	(549,570)	220,139
Balance, shares at Dec. 31, 2016	86,688,199	86,688,000
Common stock issued under stock incentive plans	$ 2,069	$ 4	2,065
Common stock issued under stock incentive plans, shares	87,367	372,000
Common stock withheld for minimum statutory taxes	$ (5,524)		(5,524)
Equity-based compensation expense	23,467		23,467
Cumulative effect of change in accounting principle	8,599				8,599
Other comprehensive gain (loss)	175,452			175,452
Other	1,249		1,249
Net income attributable to Acadia Healthcare Company, Inc. stockholders	199,835				199,835
Balance at Dec. 31, 2017	$ 2,572,871	$ 871	$ 2,517,545	$ (374,118)	$ 428,573
Balance, shares at Dec. 31, 2017	87,060,114	87,060,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Thousands, £ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Operating activities:
Net income	$ 199,589	$ 4,176	$ 111,476
Adjustments to reconcile net income to net cash provided by continuing operating activities:
Depreciation and amortization	143,010	135,103	63,550
Amortization of debt issuance costs	9,855	10,324	6,709
Equity-based compensation expense	23,467	28,345	20,472
Deferred income tax expense	31,372	28,647	43,613
(Income) loss from discontinued operations, net of taxes			(111)
Debt extinguishment costs	810	4,253	10,818
Loss on divestiture		178,809
(Gain) loss on foreign currency derivatives		(523)	1,926
Other	11,412	4,715	1,615
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	(28,570)	(15,718)	(24,954)
Other current assets	20,808	(20,648)	(2,717)
Other assets	(3,176)	(4,354)	(8,021)
Accounts payable and other accrued liabilities	(10,113)	22,693	6,868
Accrued salaries and benefits	(8,988)	(8,572)	1,658
Other liabilities	11,794	4,484	9,236
Net cash (used in) provided by continuing operating activities	401,270	371,734	242,138
Net cash used in discontinued operating activities	(1,693)	(10,256)	(1,735)
Net cash provided by operating activities	399,577	361,478	240,403
Investing activities:
Cash paid for acquisitions, net of cash acquired	(18,191)	(683,455)	(574,777)
Cash paid for capital expenditures	(274,177)	(307,472)	(276,047)
Cash paid for real estate acquisitions	(41,057)	(40,757)	(26,622)
Settlement of foreign currency derivatives		523	(1,926)
Cash received on divestitures		373,266
Other	(3,101)	(2,470)	(5,099)
Net cash used in investing activities	(336,526)	(660,365)	(884,471)
Financing activities:
Borrowings on long-term debt		1,480,000	1,150,000
Borrowings on revolving credit facility		179,000	468,000
Principal payments on revolving credit facility		(337,000)	(310,000)
Principal payments on long-term debt	(34,805)	(49,941)	(31,965)
Repayment of assumed debt		(1,348,389)	(904,467)
Repayment of long-term debt	(22,500)	(200,594)	(97,500)
Payment of debt issuance costs		(36,649)	(26,421)
Payment of premium on senior notes			(7,480)
Issuances of common stock, net		685,097	331,308
Common stock withheld for minimum statutory taxes, net	(3,455)	(8,846)	(7,762)
Excess tax benefit from equity awards			309
Other	686	(3,837)	(420)
Net cash provided by (used in) financing activities	(60,074)	358,841	563,602
Effect of exchange rate changes on cash	7,250	(14,106)	(2,359)
Net increase (decrease) in cash and cash equivalents	10,227	45,848	(82,825)
Cash and cash equivalents at beginning of the period	57,063	11,215	94,040
Cash and cash equivalents at end of the period	67,290	57,063	11,215
Supplemental Cash Flow Information:
Cash paid for interest	159,098	161,146	87,034
Cash paid for income taxes	10,291	15,483	6,911
Effect of acquisitions:
Assets acquired, excluding cash	19,649	2,516,880	1,988,634
Liabilities assumed	(1,458)	(1,616,543)	(1,024,515)
Issuance of common stock in connection with acquisition		(216,882)	(380,210)
Redeemable noncontrolling interest resulting from acquisitions			(9,132)
Cash paid for acquisitions, net of cash acquired	$ 18,191	$ 683,455	$ 574,777

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Description of Business Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States (“U.S.”), the United Kingdom (“U.K.”) and Puerto Rico. At December 31, 2017, the Company operated 582 behavioral healthcare facilities with approximately 17,800 beds in 39 states, the U.K. and Puerto Rico. Basis of Presentation The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The majority of the Company’s expenses are “cost of revenue” items. Costs that could be classified as general and administrative expenses include the Company’s corporate office costs, which were $76.4 million, $86.8 million and $68.3 million for the years ended December 31, 2017, 2016 and 2015, respectively. Certain reclassifications have been made to prior years to conform to the current year presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, cash and cash equivalent balances may exceed federally insured limits. Management believes that the Company mitigates any risks by depositing cash and investing in cash equivalents with major financial institutions. Revenue and Accounts Receivable Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. The Company receives payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; (iv) public funded sources in the U.K. (including the NHS, Clinical Commissioning Groups (“CCGs”) and local authorities in England, Scotland and Wales); and (v) individual patients and clients. Revenue is recorded in the period in which services are provided at established billing rates less contractual adjustments based on amounts reimbursable by Medicare or Medicaid under provisions of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates. The following table presents the percentage of revenue before provision for doubtful accounts generated by each payor type: Year Ended December 31, 2017 2016 2015 Commercial 19.8 % 18.7 % 23.1 % Medicare 9.8 9.4 11.7 Medicaid 27.7 25.4 33.3 U.K. public funded sources 32.6 35.8 19.5 Self-Pay 8.7 9.4 9.6 Other 1.4 1.3 2.8 Revenue before provision for doubtful accounts 100 % 100 % 100 % On a combined basis, revenue related to the Medicare and Medicaid programs were 38%, 35% and 45% of all revenue before provision for doubtful accounts for the years ended December 31, 2017, 2016 and 2015, respectively. The Company’s concentration of credit risk from other payors is reduced by the large number of payors and their geographic dispersion. The Company generated approximately 36%, 38% and 20% of its revenue for the years ended December 31, 2017, 2016 and 2015, respectively, from facilities located in the U.K. Allowance for Contractual Discounts The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the allowance for contractual discounts on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management. Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s cost report receivables were $9.0 million and $7.4 million at December 31, 2017 and 2016, respectively, and were included in other current assets in the consolidated balance sheets. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount. The net adjustments to estimated cost report settlements resulted in increases to revenue of $0.2 million, $0.7 million and $1.9 million for the years ended December 31, 2017, 2016 and 2015, respectively. Management believes that we are in substantial compliance with all applicable laws and regulations and is not aware of any material pending or threatened investigations involving allegations of wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties and exclusion from the Medicare and Medicaid programs. Allowance for Doubtful Accounts The Company’s ability to collect outstanding patient receivables from third-party payors is critical to its operating performance and cash flows. The primary collection risk with regard to patient receivables relates to uninsured patient accounts or patient accounts for which primary insurance has paid, but the portion owed by the patient remains outstanding. The Company estimates uncollectible accounts and establishes an allowance for doubtful accounts in order to adjust accounts receivable to estimated net realizable value. In evaluating the collectability of accounts receivable, the Company considers a number of factors, including the age of the accounts, historical collection experience, current economic conditions, and other relevant factors. Accounts receivable that are determined to be uncollectible based on the Company’s policies are written off to the allowance for doubtful accounts. Significant changes in payor mix or business office operations could have a significant impact on the Company’s results of operations and cash flows. A summary of activity in the Company’s allowance for doubtful accounts is as follows (in thousands): Balance at Beginning of Period Additions Charged to Costs and Expenses Accounts Written Off, Net of Recoveries Balance at End of Period Year ended December 31, 2015 $ 22,449 $ 35,127 $ (28,244 ) $ 29,332 Year ended December 31, 2016 29,332 41,909 (32,325 ) 38,916 Year ended December 31, 2017 38,916 40,918 (40,031 ) 39,803 Charity Care The Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive based on Company policies and federal and state poverty thresholds. The costs of providing charity care services were $6.6 million, $7.1 million and $4.6 million for the years ended December 31, 2017, 2016 and 2015, respectively. The estimated cost of charity care services was determined using a ratio of cost to gross charges determined from our most recently filed Medicare cost reports and applying that ratio to the gross charges associated with providing charity care for the period. Insurance The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company’s professional liability risk is insured through a wholly-owned insurance subsidiary. The Company’s wholly-owned insurance subsidiary insures the Company for professional liability losses up to $78.0 million in the aggregate. The insurance subsidiary has obtained reinsurance with unrelated commercial insurers for professional liability risks of $75.0 million in excess of a retention level of $3.0 million. The reserve for professional and general liability risks was estimated based on historical claims, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. The professional and general liability reserve was $55.0 million as of December 31, 2017, of which $22.8 million was included in other accrued liabilities and $32.2 million was included in other long-term liabilities. The professional and general liability reserve was $52.3 million as of December 31, 2016, of which $11.7 million was included in other accrued liabilities and $40.6 million was included in other long-term liabilities. The Company estimates receivables for the portion of professional and general liability reserves that are recoverable under the Company’s insurance policies. Such receivable was $22.7 million as of December 31, 2017, of which $17.6 million was included in other current assets and $5.1 million was included in other assets, and such receivable was $25.9 million as of December 31, 2016, of which $6.5 million was included in other current assets and $19.4 million was included in other assets. The Company’s statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $18.5 million as of December 31, 2017, of which $10.0 million was included in accrued salaries and benefits and $8.5 million was included in other long-term liabilities, and such liability was $16.6 million as of December 31, 2016, of which $10.0 million was included in accrued salaries and benefits and $6.6 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures. Property and Equipment and Other Long-Lived Assets Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $143.0 million, $134.8 million and $63.0 million for the years ended December 31, 2017, 2016 and 2015, respectively. The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful lives, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows. Goodwill and Indefinite-Lived Intangible Assets The Company’s goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate that the carrying value of a reporting unit may not be recoverable. The Company has two operating segments, U.S. Facilities and U.K. Facilities, for segment reporting purposes, each of which represents a reporting unit for purposes of the Company’s goodwill impairment test. Potential impairment is noted for a reporting unit if its carrying value exceeds the fair value of the reporting unit. For a reporting unit with potential impairment of goodwill, the Company determines the implied fair value of goodwill. If the carrying value of goodwill exceeds its implied fair value, an impairment loss is recorded. The Company’s annual impairment tests of goodwill and other indefinite-lived intangibles in 2017, 2016 and 2015 resulted in no impairment charges. Other Current Assets Other current assets consisted of the following (in thousands): As of December 31, 2017 2016 Other receivables $ 30,455 $ 44,975 Prepaid expenses 27,320 27,455 Insurance receivable – current portion 17,588 6,472 Income taxes receivable 15,056 11,714 Workers’ compensation deposits – current portion 10,000 10,000 Inventory 4,787 4,633 Other 2,129 2,288 Other current assets $ 107,335 $ 107,537 Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): As of December 31, 2017 2016 Accrued expenses $ 37,268 $ 37,323 Accrued interest 36,370 33,616 Unearned income 31,342 28,805 Insurance liability – current portion 22,788 11,672 Accrued property taxes 3,945 2,732 Income taxes payable 1,012 527 Other 8,488 8,283 Other accrued liabilities $ 141,213 $ 122,958 Stock Compensation The Company measures and recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, “ Compensation—Stock Compensation Earnings Per Share Basic and diluted earnings per share are calculated in accordance with FASB ASC 260, “ Earnings Per Share non-vested Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date. The Company reviews its deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Tax Act was enacted on December 22, 2017. The Tax Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time Recent Accounting Pronouncements In August 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities” 2017-12”). 2017-12 2017-12 2017-12 In January 2017, the FASB issued ASU 2017-04, “Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” 2017-04”). 2017-04 2017-04 2017-04 In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” 2016-09”). 2016-09 2016-09 2016-09 In March 2016, the FASB issued ASU 2016-02, “Leases” 2016-02”). 2016-02’s 2016-02 2016-02 right-of-use 2016-02 In May 2014, the FASB and the International Accounting Standards Board issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” 2014-09”). 2014-09’s 2014-09 Step 1: Identify the contract with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 ASU 2014-09 2014-09 2014-09 The Company will adopt ASU 2014-09 2014-09, 2014-09

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	3. Earnings Per Share The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 (in thousands except per share amounts): Year Ended December 31, 2017 2016 2015 Numerator: Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.: Income from continuing operations $ 199,835 $ 6,143 $ 112,443 Income from discontinued operations — — 111 Net income attributable to Acadia Healthcare Company, Inc. $ 199,835 $ 6,143 $ 112,554 Denominator: Weighted average shares outstanding for basic earnings per share 86,948 85,701 68,085 Effects of dilutive instruments 112 271 306 Shares used in computing diluted earnings per common share 87,060 85,972 68,391 Basic earnings per share attributable to Acadia Healthcare Company, Inc.: Income from continuing operations $ 2.30 $ 0.07 $ 1.65 Income from discontinued operations — — — Net income attributable to Acadia Healthcare Company, Inc.: $ 2.30 $ 0.07 $ 1.65 Diluted earnings per share attributable to Acadia Healthcare Company, Inc.: Income from continuing operations $ 2.30 $ 0.07 $ 1.64 Income from discontinued operations — — — Net income attributable to Acadia Healthcare Company, Inc.: $ 2.30 $ 0.07 $ 1.64 Approximately 1.4 million, 1.1 million and 0.8 million shares of common stock issuable upon exercise of outstanding stock options were excluded from the calculation of diluted earnings per share for the years ended December 31, 2017, 2016 and 2015, respectively, because their effect would have been anti-dilutive.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Acquisitions	4. Acquisitions 2017 Acquisition On November 13, 2017, we completed the acquisition of Aspire Scotland, an education facility with 36 beds located in Scotland, for cash consideration of approximately $21.3 million. 2016 U.S. Acquisitions On June 1, 2016, the Company completed the acquisition of Pocono Mountain Recovery Center (“Pocono Mountain”), an inpatient psychiatric facility with 108 beds located in Henryville, Pennsylvania, for cash consideration of approximately $25.4 million. On May 1, 2016, the Company completed the acquisition of TrustPoint Hospital (“TrustPoint”), an inpatient psychiatric facility with 100 beds located in Murfreesboro, Tennessee, for cash consideration of approximately $62.7 million. On April 1, 2016, the Company completed the acquisition of Serenity Knolls (“Serenity Knolls”), an inpatient psychiatric facility with 30 beds located in Forest Knolls, California, for cash consideration of approximately $10.0 million. Priory On February 16, 2016, the Company completed the acquisition of Priory Group No. 1 Limited (“Priory”) for a total purchase price of approximately $2.2 billion, including cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of its common stock to shareholders of Priory. Priory was the leading independent provider of behavioral healthcare services in the U.K. operating 324 facilities with approximately 7,100 beds at February 16, 2016. The Competition and Markets Authority (the “CMA”) in the U.K. reviewed the Company’s acquisition of Priory. On July 14, 2016, the CMA announced that the Company’s acquisition of Priory was referred for a phase 2 investigation unless the Company offered acceptable undertakings to address the CMA’s competition concerns relating to the provision of behavioral healthcare services in certain markets. On July 28, 2016, the CMA announced that the Company had offered undertakings to address the CMA’s concerns and that, in lieu of a phase 2 investigation, the CMA would consider the Company’s undertakings. On October 18, 2016, the Company signed a definitive agreement with BC Partners (“BC Partners”) for the sale of 21 existing U.K. behavioral health facilities and one de novo behavioral health facility with an aggregate of approximately 1,000 beds (collectively, the “U.K. Disposal Group”). On November 10, 2016, the CMA accepted the Company’s undertakings to sell the U.K. Disposal Group to BC Partners and confirmed that the divestiture satisfied the CMA’s concerns about the impact of the Company’s acquisition of Priory on competition for the provision of behavioral healthcare services in certain markets in the U.K. As a result of the CMA’s acceptance of the undertakings, the Company’s acquisition of Priory was not referred for a phase 2 investigation. On November 30, 2016, the Company completed the sale of the U.K. Disposal Group to BC Partners for £320 million cash (the “U.K. Divestiture”). In conjunction with the sale, the Company recorded a loss on divestiture of $175.0 million in the consolidated statements of income for the year ended December 31, 2016. The loss on divestiture consisted of an allocation of goodwill to the U.K. Disposal Group of $106.9 million, loss on the sale of properties of $42.0 million and estimated transaction-related expenses of $26.1 million. The allocation of goodwill was based on the fair value of the U.K. Disposal Group relative to the total fair value of the Company’s U.K. Facilities segment. The consolidated statements of income for the year ended December 31, 2016 include revenue of $154.7 million and income from continuing operations before income taxes of $81.2 million related to the U.K. Disposal Group excluding the loss on divestiture. The consolidated statements of income for the year ended December 31, 2015 include revenue of $58.5 million and income from continuing operations before income taxes of $17.0 million related to the U.K. Disposal Group excluding the loss on divestiture. Summary of Acquisitions The Company selectively seeks opportunities to expand and diversify its base of operations by acquiring additional facilities. Approximately $31.4 million of the goodwill associated with domestic acquisitions completed in 2016 is deductible for federal income tax purposes. The fair values assigned to certain assets and liabilities assumed, at the date of acquisition dates, during the year ended December 31, 2016 in connection with Priory, Serenity Knolls, Trustpoint and Pocono Mountain acquisitions (collectively the “2016 Acquisitions”) were as follows (in thousands): Priory Other Total Cash $ 10,253 $ 2,488 $ 12,741 Accounts receivable 57,832 4,264 62,096 Prepaid expenses and other current assets 7,921 103 8,024 Property and equipment 1,598,156 35,400 1,633,556 Goodwill 679,265 96,052 775,317 Intangible assets 23,200 338 23,538 Other assets 8,862 47 8,909 Total assets acquired 2,385,489 138,692 2,524,181 Accounts payable 24,203 749 24,952 Accrued salaries and benefits 39,588 918 40,506 Other accrued expenses 48,305 391 48,696 Deferred tax liabilities – noncurrent 56,462 269 56,731 Debt 1,348,389 — 1,348,389 Other liabilities 61,311 30,243 91,554 Total liabilities assumed 1,578,258 32,570 1,610,828 Net assets acquired $ 807,231 $ 106,122 $ 913,353 Other The qualitative factors comprising the goodwill acquired in the 2016 Acquisitions include efficiencies derived through synergies expected by the elimination of certain redundant corporate functions and expenses, the ability to leverage call center referrals to a broader provider base, coordination of services provided across the combined network of facilities, achievement of operating efficiencies by benchmarking performance, and applying best practices throughout the combined companies. Transaction-related expenses comprised the following costs for the years ended December 31, 2017, 2016 and 2015 (in thousands): Year Ended December 31, 2017 2016 2015 Severance and contract termination costs $ 14,709 $ 12,415 $ 8,466 Legal, accounting and other fees 9,558 21,058 17,768 Advisory and financing commitment fees — 14,850 10,337 $24,267 $48,323 $36,571

Other Intangible Assets

Other Intangible Assets	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets	5. Other Intangible Assets Other identifiable intangible assets and related accumulated amortization consisted of the following as of December 31, 2017 and 2016 (in thousands): Gross Carrying Amount Accumulated Amortization December 31, 2017 December 31, 2016 December 31, 2017 December 31, 2016 Intangible assets subject to amortization: Contract intangible assets $ 2,100 $ 2,100 $ (2,100 ) $ (2,100 ) Non-compete 1,147 1,147 (1,147 ) (1,147 ) 3,247 3,247 (3,247 ) (3,247 ) Intangible assets not subject to amortization: Licenses and accreditations 12,266 12,228 — — Trade names 60,586 57,538 — — Certificates of need 14,496 13,544 — — 87,348 83,310 — — Total $ 90,595 $ 86,557 $ (3,247 ) $ (3,247 ) Amortization expense related to definite-lived intangible assets was $0.4 million and $0.5 million for the years ended December 31, 2016 and 2015, respectively. All the Company’s defined-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Long-Term Debt	6. Long-Term Debt Long-term debt consisted of the following (in thousands): December 31, 2017 December 31, 2016 Amended and Restated Senior Credit Facility: Senior Secured Term A Loans $ 380,000 $ 400,000 Senior Secured Term B Loans 1,398,400 1,435,450 Senior Secured Revolving Line of Credit — — 6.125% Senior Notes due 2021 150,000 150,000 5.125% Senior Notes due 2022 300,000 300,000 5.625% Senior Notes due 2023 650,000 650,000 6.500% Senior Notes due 2024 390,000 390,000 9.0% and 9.5% Revenue Bonds 21,920 22,175 Less: unamortized debt issuance costs, discount and premium (50,432 ) (59,816 ) 3,239,888 3,287,809 Less: current portion (34,830 ) (34,805 ) Long-term debt $ 3,205,058 $ 3,253,004 Amended and Restated Senior Credit Facility The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”). The Company has amended the Amended and Restated Credit Agreement from time to time as described in the Company’s prior filings with the SEC. On January 25, 2016, the Company entered into the Ninth Amendment (the “Ninth Amendment”) to the Amended and Restated Credit Agreement. The Ninth Amendment modified certain definitions and provided increased flexibility to the Company in terms of its financial covenants. The Company’s baskets for permitted investments were also increased to provide increased flexibility for it to invest in non-wholly non-wholly On February 16, 2016, the Company entered into a Second Incremental Facility Amendment (the “Second Incremental Amendment”) to the Amended and Restated Credit Agreement. The Second Incremental Amendment activated a new $955.0 million incremental Term Loan B facility Tranche B-2 B-2 B-2 On May 26, 2016, the Company entered into a Tranche B-1 B-1 B-1 B-1 B-1 On September 21, 2016, the Company entered into a Tranche B-2 B-2 B-2 B-2 B-2 write-off On November 22, 2016, the Company entered into a Tenth Amendment (the “Tenth Amendment”) to the Amended and Restated Credit Agreement. The Tenth Amendment, among other things, (i) amended the negative covenant regarding dispositions, (ii) modified the collateral package to release any real property with a fair market value of less than $5.0 million and (iii) changed certain investment, indebtedness and lien baskets. On November 30, 2016, the Company entered into a Refinancing Facilities Amendment (the “Refinancing Amendment”) to the Amended and Restated Credit Agreement. The Refinancing Amendment increased the Company’s line of credit on its revolving credit facility to $500.0 million from $300.0 million and reduced its TLA Facility to $400.0 million from $600.6 million (together, the “Refinancing Facilities”). In addition, the Refinancing Amendment extended the maturity date for the Refinancing Facilities to November 30, 2021 from February 13, 2019, and lowered the Company’s effective interest rate on the line of credit on its revolving credit facility and TLA Facility by 50 basis points. In connection with the Refinancing Amendment, the Company recorded a debt extinguishment charge of $0.8 million, including the write-off On May 10, 2017, the Company entered into a Third Repricing Amendment (the “Third Repricing Amendment”) to the Amended and Restated Credit Agreement. The Third Repricing Amendment reduced the Applicable Rate with respect to the Tranche B-1 B-2 write-off The Company had $493.4 million of availability under the revolving line of credit and had standby letters of credit outstanding of $6.6 million related to security for the payment of claims required by its workers’ compensation insurance program as of December 31, 2017. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our TLA Facility of $5.0 million for March 31, 2018 to December 31, 2019, $7.5 million for March 31, 2020 to December 31, 2020, and $10.0 million for March 31, 2021 to September 30, 2021, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2021. The Company is required to repay the Tranche B-1 B-1 B-2 B-2 B-1 B-2 Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 2.75% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 1.75% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at December 31, 2017. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As of December 31, 2017, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.75%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit. The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. As of December 31, 2017, the Company was in compliance with such covenants. Senior Notes 6.125% Senior Notes due 2021 On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. 5.125% Senior Notes due 2022 On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year. 5.625% Senior Notes due 2023 On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. 6.500% Senior Notes due 2024 On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. The indentures governing the 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets. The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several. The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures. 9.0% and 9.5% Revenue Bonds On November 11, 2012, in connection with the acquisition of Park Royal, the Company assumed debt of $23.0 million. The fair market value of the debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (“9.0% and 9.5% Revenue Bonds”), respectively. The 9.0% bonds in the amount of $7.5 million have a maturity date of December 1, 2030 and require yearly principal payments beginning in 2013. The 9.5% bonds in the amount of $15.5 million have a maturity date of December 1, 2040 and require yearly principal payments beginning in 2031. The principal payments establish a bond sinking fund to be held with the trustee and shall be sufficient to redeem the principal amounts of the 9.0% and 9.5% Revenue Bonds on their respective maturity dates. As of December 30, 2017 and December 31, 2016, $2.3 million was recorded within other assets on the consolidated balance sheets related to the debt service reserve fund requirements. The yearly principal payments, which establish a bond sinking fund, will increase the debt service reserve fund requirements. The bond premium amount of $2.6 million is amortized as a reduction of interest expense over the life of the revenue bonds using the effective interest method. Debt Issuance Costs Debt issuance costs are deferred and amortized to interest expense over the term of the related debt. Debt issuance costs at December 31, 2017 were $46.5 million, net of accumulated amortization of $27.5 million. Debt issuance costs at December 31, 2016 were $55.3 million, net of accumulated amortization of $18.9 million. Amortization expense related to debt issuance costs, which is included in interest expense on the consolidated statements of operations, was $8.6 million, $8.6 million and $5.1 million, respectively, for the years ended December 31, 2017, 2016 and 2015. Other The aggregate maturities of long-term debt as of December 31, 2017 were as follows (in thousands): 2018 $ 34,830 2019 34,855 2020 44,880 2021 474,910 2022 767,240 Thereafter 1,933,605 Total $ 3,290,320

Equity

Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Equity	7. Equity Preferred Stock The Company’s amended and restated certificate of incorporation provides that up to 10,000,000 shares of preferred stock may be issued. The Board of Directors has the authority to issue preferred stock in one or more series and to fix for each series the voting powers (full, limited or none), and the designations, preferences and relative participating, optional or other special rights and qualifications, limitations or restrictions on the stock and the number of shares constituting any series and the designations of this series, without any further vote or action by the stockholders. Common Stock On March 3, 2016, the Company held a Special Meeting of Stockholders, where the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 90,000,000 to 180,000,000 (the “Amendment”). On March 3, 2016, the Company filed the Amendment with the Secretary of State of the State of Delaware. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters on which stockholders may vote. There are no preemptive, conversion, redemption or sinking fund provisions applicable to shares of the Company’s common stock. In the event of liquidation, dissolution or winding up, holders of the Company’s common stock are entitled to share ratably in the assets available for distribution, subject to any prior rights of any holders of preferred stock then outstanding. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the Amended and Restated Senior Credit Facility imposes restrictions on the Company’s ability to pay dividends. Equity Offerings On January 12, 2016, the Company completed the offering of 11,500,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $61.00 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $15.8 million and additional offering-related costs of $0.7 million, were $685.0 million. The Company used the net offering proceeds to fund a portion of the purchase price for the acquisition of Priory. On February 16, 2016, the Company completed the acquisition of Priory for a total purchase price of approximately $2.2 billion including cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of common stock to shareholders of Priory.

Equity-Based Compensation

Equity-Based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity-Based Compensation	8. Equity-Based Compensation Equity Incentive Plans The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee The Company recognized $23.5 million, $28.3 million and $20.5 million in equity-based compensation expense for the years ended December 31, 2017, 2016 and 2015, respectively. Stock compensation expense for the year ended December 31, 2017 included forfeiture adjustments and restricted stock unit adjustments based on actual performance compared to vesting targets of $(5.7) million. As of December 31, 2017, there was $42.5 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.2 years. As of December 31, 2017, there were no warrants outstanding and exercisable. The Company recognized a deferred income tax benefit of $9.2 million and $10.7 million for the years ended December 31, 2017 and 2016, respectively, related to equity-based compensation expense. Stock option activity during 2016 and 2017 was as follows (aggregate intrinsic value in thousands): Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Options outstanding at January 1, 2016 694,743 $ 42.87 7.70 $ 20,717 Options granted 503,850 57.98 9.28 297 Options exercised (57,397 ) 31.92 N/A 1,530 Options cancelled (140,250 ) 57.13 N/A N/A Options outstanding at December 31, 2016 1,000,946 49.42 7.80 8,166 Options granted 259,300 42.25 9.30 205 Options exercised (87,367 ) 25.92 N/A 1,636 Options cancelled (198,313 ) 54.71 N/A N/A Options outstanding at December 31, 2017 974,566 $ 47.89 7.46 $ 3,802 Options exercisable at December 31, 2016 288,959 $ 42.81 6.22 $ 6,111 Options exercisable at December 31, 2017 405,634 $ 41.20 6.05 $ 3,549 Restricted stock activity during 2016 and 2017 was as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2016 944,562 $ 52.74 Granted 387,347 55.38 Cancelled (122,178 ) 57.02 Vested (365,312 ) 47.18 Unvested at December 31, 2016 844,419 $ 55.76 Granted 404,224 42.38 Cancelled (145,981 ) 55.03 Vested (292,794 ) 53.07 Unvested at December 31, 2017 809,868 $ 50.19 Restricted stock unit activity during 2016 and 2017 was as follows: Number of Units Weighted Average Grant-Date Fair Value Unvested at January 1, 2016 218,084 $ 56.97 Granted 230,750 56.95 Cancelled — — Vested (175,235 ) 52.71 Unvested at December 31, 2016 273,599 $ 59.68 Granted 219,840 43.23 Cancelled — — Vested (132,530 ) 58.67 Unvested at December 31, 2017 360,909 $ 50.04 The grant-date fair value of the Company’s stock options is estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2017 and 2016: December 31, 2017 December 31, 2016 Weighted average grant-date fair value of options $ 14.39 $ 18.96 Risk-free interest rate 2.0 % 1.4 % Expected volatility 33 % 33 % Expected life (in years) 5.5 5.5 The Company’s estimate of expected volatility for stock options is based upon the volatility of guideline companies given the lack of sufficient historical trading experience of the Company’s common stock. The risk-free interest rate is the approximate yield on U.S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The Company adopted ASU 2016-09 Excess tax benefits/deficiencies are generated when the deduction for tax purposes is greater/less than the compensation cost for financial reporting purposes. Upon adoption of ASU 2016-09, paid-in 2016-09 Income tax expense (benefit) from continuing operations consists of the following for the periods presented (in thousands): Year Ended December 31, 2017 2016 2015 Current: Federal $ 3,325 $ 572 $ (218 ) State 680 (863 ) 4,078 Foreign 1,832 423 5,915 Total current 5,837 132 9,775 Deferred: Federal 27,179 45,077 40,635 State 4,408 1,491 5,349 Foreign (215 ) (17,921 ) (2,371 ) Total deferred provision 31,372 28,647 43,613 Provision for income taxes $ 37,209 $ 28,779 $ 53,388 A reconciliation of the U.S. federal statutory rate, from continuing operations, to the effective tax rate is as follows for the periods presented: Year Ended December 31, 2017 2016 2015 U.S. federal statutory rate on income before income taxes 35.0 % 35.0 % 35.0 % Impact of foreign operations (14.1 ) (13.5 ) (10.0 ) Impact of foreign divestiture — 39.2 — Effects of statutory rate change (8.5 ) (14.5 ) — State income taxes, net of federal tax effect 2.1 7.5 4.8 Permanent differences 1.8 8.3 4.2 Transaction related items — 25.9 — Change in valuation allowance 1.6 2.8 1.2 Unrecognized tax benefit release (0.8 ) (7.2 ) — Other (1.4 ) 3.8 (2.8 ) Effective income tax rate 15.7 % 87.3 % 32.4 % The domestic and foreign components of income (loss) from continuing operations before income taxes are as follows (in thousands): Year Ended December 31, 2017 2016 2015 Foreign $ 120,905 $ (144,717 ) $ 28,316 Domestic 115,893 177,672 136,437 Total $ 236,798 $ 32,955 $ 164,753 The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities of the Company at December 31, 2017 and December 31, 2016 were as follows (in thousands): December 31, 2017 2016 Deferred tax assets: Net operating losses and tax credit carryforwards – federal and state $ 29,409 $ 37,638 Bad debt allowance 827 15,381 Accrued compensation and severance 14,179 23,379 Pension reserves 1,494 697 Insurance reserves 13,483 17,468 Leases 5,332 2,926 Accrued expenses 3,114 — Interest carryforwards 5,074 — Other assets 1,747 2,038 Total gross deferred tax assets 74,659 99,527 Less: valuation allowance (21,155 ) (16,031 ) Deferred tax assets 53,504 83,496 Deferred tax liabilities: Fixed asset basis difference (54,214 ) (45,510 ) Prepaid items (1,490 ) (1,324 ) Intangible assets (70,820 ) (77,655 ) Accrued expenses — (4,531 ) Other liabilities (3,582 ) (29,216 ) Total deferred tax liabilities (130,106 ) (158,236 ) Total net deferred tax liability $ (76,602 ) $ (74,740 ) The Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. As of December 31, 2017 and 2016, the Company carried a valuation allowance against deferred tax assets of $21.2 million and $16.0 million, respectively. The domestic net operating loss carryforwards are approximately $28.4 million as of December 31, 2016. There are no domestic net operating loss carryforwards at December 31, 2017. The foreign net operating loss carryforwards as of December 31, 2017 and 2016 are approximately $93.9 million and $92.2 million, respectively, and have no expiration. The Company has state net operating loss carryforwards at December 31, 2017 and 2016 of approximately $256.9 million and $223.3 million, respectively. These net operating loss carryforwards, if not used to offset future taxable income, will expire from 2018 to 2036. In addition, the Company has certain state tax credits of $0.9 million which will begin to expire in 2026 if not utilized. Income taxes receivable was $15.1 million and $11.7 million at December 31, 2017 and 2016, respectively, and was included in other current assets in the consolidated balance sheets. Income taxes payable of $1.0 million and $0.5 million at December 31, 2017 and 2016 was included in other accrued liabilities in the consolidated balance sheets. The Company has recorded income taxes payable related to unrecognized tax benefits of $6.4 million and $7.8 million at December 31, 2017 and 2016, respectively, in other liabilities in the consolidated balance sheets. A reconciliation of the beginning and ending amount of unrecognized income tax benefits net of the federal benefit is as follows (in thousands): 2017 2016 2015 Balance at January 1 $ 6,949 $ 4,511 $ 2,923 Additions based on tax positions related to the current year 5,488 — 1,516 Additions for tax positions of prior years 95 5,427 2,874 Reductions as a result of the lapse of applicable statutes of limitations (6,428 ) (2,989 ) (2,802 ) Balance at December 31 $ 6,104 $ 6,949 $ 4,511 The Company recognizes interest and penalties related to unrecognized tax benefits in its consolidated balance sheets. As of December 31, 2017 and 2016, the cumulative amounts recognized were $0.1 million and $0.9 million, respectively. It is possible the amount of unrecognized tax benefit could change in the next twelve months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, management does not anticipate the change will have a material impact on the Company’s consolidated financial statements. The Company’s uncertain tax positions are related to tax years that remain subject to examination by the relevant taxing authorities. The Company and its subsidiaries file income tax returns in federal and in many state and local jurisdictions as well as foreign jurisdictions. The Company may be subject to examination by the Internal Revenue Service (“IRS”) for calendar year 2014 through 2016. Additionally, any net operating losses that were generated in prior years and utilized in these years may also be subject to examination by the IRS. In foreign jurisdictions, the Company may be subject to examination for calendar years 2013 through 2016. Generally, for state tax purposes, the Company’s 2011 through 2016 tax years remain open for examination by the tax authorities. At the date of this report there were no audits or inquires that had progressed sufficiently to predict their ultimate outcome. One of the Company’s Puerto Rico subsidiaries was granted a tax exemption for which a tax credit of up to 15% of eligible payroll expenses is available to offset up to 50% of the income taxes attributed to that entity. It is the Company’s intention to utilize its earnings in the foreign operations for an indefinite period of time. At December 31, 2017, there were no undistributed earnings of the foreign subsidiaries as the cumulative net loss of its foreign subsidiaries exceeds the cumulative earnings from its foreign subsidiaries. The cumulative net loss of the Company’s foreign subsidiaries includes a loss on divestiture of $175.0 million related to the U.K. Divestiture on November 30, 2016. If a deferred tax liability for undistributed foreign earnings becomes required, it would be significantly impacted by the Tax Act, the source location and amount of the distribution, the underlying tax rate already paid on the earnings, foreign withholding taxes, foreign currency translation adjustment and the opportunity to use foreign tax credits. U.S. Tax Reform On December 22, 2017, Public Law 115-97, one-time one-time low-taxed At December 31, 2017, the Company has not completed its accounting for the tax effects of enactment of the Tax Act; however, in certain cases, as described below, the Company has made a reasonable estimate of the effects on our existing deferred tax balances. In other cases, the Company has not been able to make a reasonable estimate and continues to account for those items based on its existing accounting under ASC 740 and the provisions of the tax laws that were in effect immediately prior to enactment of the Tax Act. For the items for which the Company was able to determine a reasonable estimate, the Company recognized a provisional amount of $20.2 million, which is included as a component of income tax expense from continuing operations. ASC 740 requires the Company to recognize the effect of tax law changes in the period of enactment. However, the SEC staff issued SAB 118 which will allow the Company to record provisional amounts during a measurement period similarly to the measurement period used when accounting for business combinations. The Company will continue to assess the impact of the recently enacted tax law on its business and consolidated financial statements. Provisional Amounts Deferred Tax Assets and Liabilities The Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. As a result of the reduction in the corporate income tax rate, the Company is required to revalue its net deferred tax assets and liabilities to account for the future impact of lower corporate tax rates on this deferred amount and record any change in the value of such asset or liability as a one-time non-cash U.S. Tax on Foreign Earnings The one-time one-time The Company’s accounting for Global Intangible Low-Taxed

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	10. Derivatives The Company entered into foreign currency forward contracts during the years ended December 31, 2017 and 2016 in connection with (i) acquisitions in the U.K. and (ii) certain transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between US Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers. The foreign currency contracts entered into during the year ended December 31, 2016 resulted in gains of $0.5 million which have been recorded in the consolidated statements of income. In May 2016, the Company entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated GBP-denominated USD-denominated The Company has designated the cross currency swap agreements and certain forward contracts entered into during 2016 and 2017 as qualifying hedging instruments and is accounting for these as net investment hedges. At December 31, 2017 and 2016, the fair value of these derivatives are $13.0 million and $73.5 million, respectively, and are recorded as an asset within derivative instruments on the consolidated balance sheets. The gains and losses resulting from fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive income as the swaps are effective in hedging the designated risk. Cash flows related to the cross currency swaps are included in operating activities in the consolidated statements of cash flows.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	11. Fair Value Measurements The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments. The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 9.0% and 9.5% Revenue Bonds, derivative instruments and contingent consideration liability as of December 31, 2017 and 2016 were as follows (in thousands): Carrying Amount Fair Value December 31, December 31, 2017 2016 2017 2016 Amended and Restated Senior Credit Facility $ 1,749,185 $ 1,799,993 $ 1,749,185 $ 1,799,993 6.125% Senior Notes due 2021 $ 148,098 $ 147,574 $ 150,134 $ 152,186 5.125% Senior Notes due 2022 $ 296,174 $ 295,442 $ 296,914 $ 293,595 5.625% Senior Notes due 2023 $ 641,891 $ 640,574 $ 651,519 $ 640,574 6.500% Senior Notes due 2024 $ 382,251 $ 381,268 $ 397,541 $ 389,847 9.0% and 9.5% Revenue Bonds $ 22,289 $ 22,959 $ 22,289 $ 22,959 Derivative instruments $ 12,997 $ 73,509 $ 12,997 $ 73,509 Contingent consideration liabilities $ — $ 107 $ — $ 107 The Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes and 9.0% and 9.5% Revenue Bonds were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates. The fair values of the derivative instruments were categorized as Level 2 in the GAAP fair value hierarchy and were based on observable market inputs including applicable exchange rates and interest rates. The fair value of the contingent consideration liabilities were categorized as Level 3 in the GAAP fair value hierarchy. The contingent consideration liabilities were valued using a probability-weighted discounted cash flow method. This analysis reflected the contractual terms of the purchase agreements and utilized assumptions with regard to future earnings, probabilities of achieving such future earnings and a discount rate.

Leases

Leases	12 Months Ended
	Dec. 31, 2017
Leases [Abstract]
Leases	12. Leases The Company is obligated under certain operating leases to rent space for its facilities and other office space. The original terms of the leases typically range from five to 30 years, with optional renewal periods. Aggregate minimum lease payments under non-cancelable 2018 $ 69,613 2019 64,556 2020 60,156 2021 56,620 2022 51,071 Thereafter 835,369 Total minimum rental obligations $ 1,137,385 During the years ended December 31, 2017, 2016 and 2015, rent expense was $76.8 million, $73.3 million and $32.5 million, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies The Company is, from time to time, subject to various claims, governmental investigations and regulatory actions that arise in the ordinary course of the Company’s business, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Under the federal False Claims Act, private parties have the right to bring qui tam,

Noncontrolling Interests

Noncontrolling Interests	12 Months Ended
	Dec. 31, 2017
Noncontrolling Interest [Abstract]
Noncontrolling Interests	14. Noncontrolling Interests Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners in non-wholly non-wholly The components of redeemable noncontrolling interests are as follows (in thousands): Balance at January 1, 2016 $ 8,055 Acquisition of redeemable noncontrolling interests 11,666 Net loss attributable to noncontrolling interests (1,967 ) Balance at December 31, 2016 17,754 Acquisition of redeemable noncontrolling interests 4,909 Net loss attributable to noncontrolling interests (246 ) Balance at December 31, 2017 $ 22,417

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segment Information	15. Segment Information The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its facilities in the United States (the “U.S. Facilities”) and its facilities in the United Kingdom (the “U.K. Facilities”) separately to assess performance and make decisions, the Company’s operating segments include its U.S. Facilities and U.K. Facilities. At December 31, 2017, the U.S. Facilities included 209 behavioral healthcare facilities with approximately 8,900 beds in 39 states and Puerto Rico, and the U.K. Facilities included 373 behavioral healthcare facilities with approximately 8,900 beds in the U.K. The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands): Year Ended December 31, 2017 2016 2015 Revenue: U.S. Facilities $ 1,809,844 $ 1,698,525 $ 1,426,205 U.K. Facilities 1,026,472 1,110,361 360,698 Corporate and Other — 2,028 7,589 $ 2,836,316 $ 2,810,914 $ 1,794,492 Segment EBITDA (1) U.S. Facilities $ 475,260 $ 443,341 $ 377,587 U.K. Facilities 198,566 245,046 90,035 Corporate and Other (69,467 ) (79,797 ) (62,790 ) $ 604,359 $ 608,590 $ 404,832 Year Ended December 31, 2017 2016 2015 Segment EBITDA(1) $ 604,359 $ 608,590 $ 404,832 Plus (less): Equity-based compensation expense (23,467 ) (28,345 ) (20,472 ) Debt extinguishment costs (810 ) (4,253 ) (10,818 ) Loss on divestiture — (178,809 ) — Gain (loss) on foreign currency derivatives — 523 (1,926 ) Transaction-related expenses (24,267 ) (48,323 ) (36,571 ) Interest expense, net (176,007 ) (181,325 ) (106,742 ) Depreciation and amortization (143,010 ) (135,103 ) (63,550 ) Income from continuing operations before income taxes $ 236,798 $ 32,955 $ 164,753 U.S. Facilities U.K. Facilities Corporate and Other Consolidated Goodwill: Balance at January 1, 2017 $ 2,041,795 $ 639,393 $ — $ 2,681,188 Increase from 2017 acquisition — 15,302 — 15,302 Foreign currency translation — 60,770 — 60,770 Purchase price allocation and other 797 (6,883 ) — (6,086 ) Balance at December 31, 2017 $ 2,042,592 $ 708,582 $ — $ 2,751,174 December 31, 2017 2016 Assets (2) U.S. Facilities $ 3,567,126 $ 3,382,167 U.K. Facilities 2,647,150 2,441,018 Corporate and Other 210,226 201,541 $ 6,424,502 $ 6,024,726 (1) Segment EBITDA is defined as income from continuing operations before provision for income taxes, equity-based compensation expense, debt extinguishment costs, gain on foreign currency derivatives, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. (2) Assets include property and equipment for the U.S. Facilities of $1.2 billion, U.K. Facilities of $1.8 billion and corporate and other of $49.2 million at December 31, 2017. Assets include property and equipment for the U.S. Facilities of $1.0 billion, U.K. Facilities of $1.7 billion and corporate and other of $27.1 million at December 31, 2016.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Employee Benefit Plans	16. Employee Benefit Plans Defined Contribution Plan The Company maintains a qualified defined contribution 401(k) plan covering substantially all of its employees in the U.S. The Company may, at its discretion, make contributions to the plan. The Company contributed $0.2 million, $0.1 million, and $0.1 million to the 401(k) plan for the years ended December 31, 2017, 2016 and 2015, respectively. Partnerships in Care Pension Plan As part of the acquisition of Partnerships in Care on July 1, 2014, the Company assumed a frozen contributory defined benefit retirement plan (“Partnerships in Care Pension Plan”) covering substantially all of the employees of Partnerships in Care and its subsidiaries prior to May 1, 2005 at which time, the Partnerships in Care Plan was frozen to new participants. Effective May 2015, the active participants no longer accrue benefits. The benefits under the Partnerships in Care Pension Plan were primarily based on years of service and final average earnings. The Company accounts for the Partnerships in Care Pension Plan in accordance with ASC 715-30 715-30”). 715-30, year-end. The following table summarizes the funded status (unfunded liability) of the Partnerships in Care Pension Plan based upon actuarial valuations prepared as of December 31, 2017 and 2016 (in thousands): 2017 2016 Projected benefit obligation $ 67,288 $ 64,162 Fair value of plan assets 58,493 53,462 Unfunded liability $ 8,795 $ 10,700 The following table summarizes changes in the Partnerships in Care Pension Plan net pension liability as of December 31, 2017 and 2016 (in thousands): 2017 2016 Net pension liability at beginning of period $ 10,700 $ 2,821 Employer contributions (809 ) (740 ) Net pension expense (benefit) 426 339 Pension liability adjustment (2,544 ) 8,781 Foreign currency translation gain (loss) 1,022 (501 ) Net pension liability at end of period $ 8,795 $ 10,700 A pension liability of $8.8 million and $10.7 million were recorded within other liabilities on the consolidated balance sheets as of December 31, 2017 and 2016. The following assumptions were used to determine the plan benefit obligation: Discount rate 2.5 % 2.7 % Compensation increase rate 2.3 % 2.4 % Measurement date December 31, 2017 December 31, 2016 A summary of the components of net pension plan expense for the year ended December 31, 2017 and 2016 is as follows (in thousands): 2017 2016 Interest cost on projected benefit obligation $ 1,738 $ 1,964 Expected return on assets (1,312 ) (1,625 ) Total pension plan expense (benefit) $ 426 $ 339 Assumptions used to determine the net periodic pension plan expense for the year ended December 31, 2017 and 2016 were as follows: 2017 2016 Discount rate 2.5 % 2.7 % Expected long-term rate of return on plan assets 2.5 % 2.7 % The Company recognizes changes in the funded status of the pension plan as a direct increase or decrease to stockholders’ equity through accumulated other comprehensive income. The accumulated other comprehensive income (loss) related to the Partnerships in Care Pension Plan for the years ended December 31, 2017, 2016 and 2015 was $(4.1) million ($(4.5) million net of taxes), $(7.4) million ($6.1 million net of taxes) and $2.6 million ($(1.7) million net of taxes), respectively. The trustees of the Partnerships in Care Pension Plan are required to invest assets in the best interest of the Partnerships in Care Pension Plan’s members and also ensure liquid assets are available to make benefit payments as they become due. Performance of the Partnerships in Care Pension Plan’s assets are monitored quarterly, at a minimum, and asset allocations are adjusted as needed. The Partnerships in Care Pension Plan’s weighted-average asset allocations by asset category as of December 31, 2017 and 2016 were as follows: December 31, 2017 December 31, 2016 Cash and cash equivalents 0.7 % 1.5 % U.K. government obligation 19.0 % 14.5 % Annuity contracts 38.6 % 41.6 % Equity securities 29.4 % 26.3 % Debt securities 9.9 % 12.1 % Other 2.4 % 4.0 % As of December 31, 2017 and 2016, the Partnerships in Care Pension Plan cash and cash equivalents were classified as Level 1 in the GAAP fair value hierarchy. Fair values were based on utilizing quoted prices (unadjusted) in active markets for identical assets. The U.K. government obligations, annuity contracts, equity securities, debt securities and other investments were classified as Level 2 in the GAAP fair value hierarchy. Fair values were based on data points that are observable, such as quoted prices, interest rates and yield curves.

Other Comprehensive Loss

Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Other Comprehensive Loss	17. Other Comprehensive Loss The components of accumulated other comprehensive loss are as follows (in thousands): Foreign Currency Translation Adjustments Change in Fair Value of Derivative Instruments Pension Plan Total Balance at January 1, 2015 $ (66,206 ) $ — $ (2,164 ) $ (68,370 ) Foreign currency translation loss (40,103 ) — — (40,103 ) Pension liability adjustment, net of tax of $0.9 million — — 3,826 3,826 Balance at December 31, 2015 (106,309 ) — 1,662 (104,647 ) Foreign currency translation loss (477,772 ) — — (477,772 ) Gain on derivative instruments, net of tax of $29.1 million — 40,598 — 40,598 Pension liability adjustment, net of tax of $(1.3) million — — (7,749 ) (7,749 ) Balance at December 31, 2016 (584,081 ) 40,598 (6,087 ) (549,570 ) Foreign currency translation gain 207,341 — — 207,341 Loss on derivative instruments, net of tax of $(22.9) million — (33,431 ) — (33,431 ) Pension liability adjustment, net of tax of $0.4 million — — 1,542 1,542 Balance at December 31, 2017 $ (376,740 ) $ 7,167 $ (4,545 ) $ (374,118 )

Quarterly Information (Unaudite

Quarterly Information (Unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Information (Unaudited)	18. Quarterly Information (Unaudited) The tables below present summarized unaudited quarterly results of operations for the years ended December 31, 2017 and 2016. Management believes that all necessary adjustments have been included in the amounts stated below for a fair presentation of the results of operations for the periods presented when read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2017 and 2016. Results of operations for a particular quarter are not necessarily indicative of results of operations for an annual period and are not predictive of future periods. Quarter Ended March 31, June 30, September 30, December 31, (In thousands except per share amounts) 2017: Revenue $ 679,194 $ 715,896 $ 716,714 $ 724,512 Income from continuing operations before income taxes $ 48,484 $ 66,216 $ 61,459 $ 60,639 Net income attributable to Acadia Healthcare Company, Inc. stockholders $ 34,958 $ 49,630 $ 45,618 $ 69,629 (1) Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders $ 0.40 $ 0.57 $ 0.52 $ 0.80 (1) Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders $ 0.40 $ 0.57 $ 0.52 $ 0.80 (1) 2016: Revenue $ 616,813 $ 756,548 $ 734,665 $ 702,888 Income from continuing operations before income taxes $ 32,479 $ 73,852 $ (115,814 ) (2) $ 42,438 (3) Net income attributable to Acadia Healthcare Company, Inc. stockholders $ 25,688 $ 56,445 $ (117,808 ) (2) $ 41,818 (3) Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders $ 0.31 $ 0.65 $ (1.36 ) (2) $ 0.48 (3) Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders $ 0.31 $ 0.65 $ (1.36 ) (2) $ 0.48 (3) (1) Includes a one-time (2) Includes loss on divestiture of $174.7 million and debt extinguishment costs of $3.4 million, or $142.0 million net of taxes, in connection with the U.K. Divestiture and the repricing of our Tranche B-2 (3) Includes loss on divestiture of $4.0 million and debt extinguishment costs of $0.8 million, or $3.1 million net of taxes, in connection with the Company’s divestitures and the Refinancing Amendment.

Financial Information for the C

Financial Information for the Company and Its Subsidiaries	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financial Information for the Company and Its Subsidiaries	19. Financial Information for the Company and Its Subsidiaries The Company conducts substantially all of its business through its subsidiaries. The 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% senior notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Presented below is condensed consolidating financial information for the Company and its subsidiaries as of December 31, 2017 and 2016, and for the years ended December 31, 2017, 2016 and 2015. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors, the combined non-guarantor Acadia Healthcare Company, Inc. Condensed Consolidating Balance Sheets December 31, 2017 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Current assets: Cash and cash equivalents $ — $ 46,860 $ 20,430 $ — $ 67,290 Accounts receivable, net — 230,890 66,035 — 296,925 Other current assets — 85,746 21,589 — 107,335 Total current assets — 363,496 108,054 — 471,550 Property and equipment, net — 1,086,802 1,961,328 — 3,048,130 Goodwill — 1,936,057 815,117 — 2,751,174 Intangible assets, net — 57,628 29,720 — 87,348 Deferred tax assets – noncurrent 2,370 — 3,731 (2,370 ) 3,731 Derivative instruments 12,997 — — — 12,997 Investment in subsidiaries 5,429,386 — — (5,429,386 ) — Other assets 381,913 38,860 7,807 (379,008 ) 49,572 Total assets $ 5,826,666 $ 3,482,843 $ 2,925,757 $ (5,810,764 ) $ 6,424,502 Current liabilities: Current portion of long-term debt $ 34,550 $ — $ 280 $ — $ 34,830 Accounts payable — 70,767 31,532 — 102,299 Accrued salaries and benefits — 69,057 29,990 — 99,047 Other accrued liabilities 36,196 27,676 77,341 — 141,213 Total current liabilities 70,746 167,500 139,143 — 377,389 Long-term debt 3,183,049 — 401,017 (379,008 ) 3,205,058 Deferred tax liabilities – noncurrent — 27,975 54,728 (2,370 ) 80,333 Other liabilities — 103,112 63,322 — 166,434 Total liabilities 3,253,795 298,587 658,210 (381,378 ) 3,829,214 Redeemable noncontrolling interests — — 22,417 — 22,417 Total equity 2,572,871 3,184,256 2,245,130 (5,429,386 ) 2,572,871 Total liabilities and equity $ 5,826,666 $ 3,482,843 $ 2,925,757 $ (5,810,764 ) $ 6,424,502 Acadia Healthcare Company, Inc. Condensed Consolidating Balance Sheets December 31, 2016 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Current assets: Cash and cash equivalents $ — $ 15,681 $ 41,382 $ — $ 57,063 Accounts receivable, net — 209,124 54,203 — 263,327 Other current assets — 61,724 45,813 — 107,537 Total current assets — 286,529 141,398 — 427,927 Property and equipment, net — 940,880 1,762,815 — 2,703,695 Goodwill — 1,935,260 745,928 — 2,681,188 Intangible assets, net — 56,676 26,634 — 83,310 Deferred tax assets – noncurrent 13,522 — 4,606 (14,348 ) 3,780 Derivative instruments 73,509 — — — 73,509 Investment in subsidiaries 4,885,865 — — (4,885,865 ) — Other assets 493,294 40,480 7,189 (489,646 ) 51,317 Total assets $ 5,466,190 $ 3,259,825 $ 2,688,570 $ (5,389,859 ) $ 6,024,726 Current liabilities: Current portion of long-term debt $ 34,550 $ — $ 255 $ — $ 34,805 Accounts payable — 49,205 30,829 — 80,034 Accrued salaries and benefits — 72,835 32,233 — 105,068 Other accrued liabilities 33,616 24,375 64,967 — 122,958 Total current liabilities 68,166 146,415 128,284 — 342,865 Long-term debt 3,230,300 — 512,350 (489,646 ) 3,253,004 Deferred tax liabilities – noncurrent — 40,574 52,294 (14,348 ) 78,520 Other liabilities — 101,938 62,921 — 164,859 Total liabilities 3,298,466 288,927 755,849 (503,994 ) 3,839,248 Redeemable noncontrolling interests — — 17,754 — 17,754 Total equity 2,167,724 2,970,898 1,914,967 (4,885,865 ) 2,167,724 Total liabilities and equity $ 5,466,190 $ 3,259,825 $ 2,688,570 $ (5,389,859 ) $ 6,024,726 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Comprehensive Income Year Ended December 31, 2017 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Revenue before provision for doubtful accounts $ — $ 1,746,656 $ 1,130,578 $ — $ 2,877,234 Provision for doubtful accounts — (35,636 ) (5,282 ) — (40,918 ) Revenue — 1,711,020 1,125,296 — 2,836,316 Salaries, wages and benefits 23,467 902,180 610,513 — 1,536,160 Professional fees — 93,991 102,232 — 196,223 Supplies — 75,248 39,191 — 114,439 Rents and leases — 33,365 43,410 — 76,775 Other operating expenses — 217,900 113,927 — 331,827 Depreciation and amortization — 66,482 76,528 — 143,010 Interest expense, net 61,872 81,274 32,861 — 176,007 Debt extinguishment costs 810 — — — 810 Transaction-related expenses — 11,236 13,031 — 24,267 Total expenses 86,149 1,481,676 1,031,693 — 2,599,518 (Loss) income from continuing operations before income taxes (86,149 ) 229,344 93,603 — 236,798 Equity in earnings of subsidiaries 259,282 — — (259,282 ) — (Benefit from) provision for income taxes (26,456 ) 69,882 (6,217 ) — 37,209 Income (loss) from continuing operations 199,589 159,462 99,820 (259,282 ) 199,589 Income from discontinued operations, net of income taxes — — — — — Net income (loss) 199,589 159,462 99,820 (259,282 ) 199,589 Net loss attributable to noncontrolling interests — — 246 — 246 Net income attributable to Acadia Healthcare Company, Inc. $ 199,589 $ 159,462 $ 100,066 $ (259,282 ) $ 199,835 Other comprehensive income: Foreign currency translation gain — — 207,341 — 207,341 Loss on derivative instruments (33,431 ) — — — (33,431 ) Pension liability adjustment, net — — 1,542 — 1,542 Other comprehensive income (33,431 ) — 208,883 — 175,452 Comprehensive income (loss) $ 166,158 $ 159,462 $ 308,949 $ (259,282 ) $ 375,287 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Comprehensive Income Year Ended December 31, 2016 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Revenue before provision for doubtful accounts $ — $ 1,662,734 $ 1,190,089 $ — $ 2,852,823 Provision for doubtful accounts — (38,349 ) (3,560 ) — (41,909 ) Revenue — 1,624,385 1,186,529 — 2,810,914 Salaries, wages and benefits 28,345 865,104 648,405 — 1,541,854 Professional fees — 89,062 96,424 — 185,486 Supplies — 76,246 41,179 — 117,425 Rents and leases — 34,540 38,808 — 73,348 Other operating expenses — 206,308 106,248 — 312,556 Depreciation and amortization — 58,018 77,085 — 135,103 Interest expense, net 50,921 75,848 54,556 — 181,325 Debt extinguishment costs 4,253 — — — 4,253 Loss on divestiture — 778 178,031 — 178,809 Gain on foreign currency derivatives (523 ) — — — (523 ) Transaction-related expenses — 32,173 16,150 — 48,323 Total expenses 82,996 1,438,077 1,256,886 — 2,777,959 (Loss) income from continuing operations before income taxes (82,996 ) 186,308 (70,357 ) — 32,955 Equity in earnings of subsidiaries 65,560 — — (65,560 ) — (Benefit from) provision for income taxes (21,612 ) 68,335 (17,944 ) — 28,779 Income (loss) from continuing operations 4,176 117,973 (52,413 ) (65,560 ) 4,176 Income from discontinued operations, net of income taxes — — — — — Net income (loss) 4,176 117,973 (52,413 ) (65,560 ) 4,176 Net loss attributable to noncontrolling interests — — 1,967 — 1,967 Net income attributable to Acadia Healthcare Company, Inc. $ 4,176 $ 117,973 $ (50,446 ) $ (65,560 ) $ 6,143 Other comprehensive income: Foreign currency translation loss — — (477,772 ) — (477,772 ) Gain on derivative instruments 40,598 — — — 40,598 Pension liability adjustment, net — — (7,749 ) — (7,749 ) Other comprehensive income 40,598 — (485,521 ) — (444,923 ) Comprehensive income (loss) $ 44,774 $ 117,973 $ (535,967 ) $ (65,560 ) $ (438,780 ) Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Comprehensive Income Year Ended December 31, 2015 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Revenue before provision for doubtful accounts $ — $ 1,415,016 $ 414,603 $ — $ 1,829,619 Provision for doubtful accounts — (32,614 ) (2,513 ) — (35,127 ) Revenue — 1,382,402 412,090 — 1,794,492 Salaries, wages and benefits 20,472 726,215 227,045 — 973,732 Professional fees — 83,422 33,041 — 116,463 Supplies — 65,077 15,586 — 80,663 Rents and leases — 29,094 3,434 — 32,528 Other operating expenses — 170,018 36,728 — 206,746 Depreciation and amortization — 41,768 21,782 — 63,550 Interest expense, net 68,533 17,476 20,733 — 106,742 Debt extinguishment costs 10,818 — — — 10,818 Loss on foreign currency derivatives 1,926 — — — 1,926 Transaction-related expenses — 24,914 11,657 — 36,571 Total expenses 101,749 1,157,984 370,006 — 1,629,739 (Loss) income from continuing operations before income taxes (101,749 ) 224,418 42,084 — 164,753 Equity in earnings of subsidiaries 176,178 — — (176,178 ) — (Benefit from) provision for income taxes (37,047 ) 85,765 4,670 — 53,388 Income (loss) from continuing operations 111,476 138,653 37,414 (176,178 ) 111,365 Income from discontinued operations, net of income taxes — 111 — — 111 Net income (loss) 111,476 138,764 37,414 (176,178 ) 111,476 Net loss attributable to noncontrolling interests — — 1,078 — 1,078 Net income attributable to Acadia Healthcare Company, Inc. $ 111,476 $ 138,764 $ 38,492 $ (176,178 ) $ 112,554 Other comprehensive income: Foreign currency translation loss — — (40,103 ) — (40,103 ) Pension liability adjustment, net — — 3,826 — 3,826 Other comprehensive income — — (36,277 ) — (36,277 ) Comprehensive income (loss) $ 111,476 $ 138,764 $ 2,215 $ (176,178 ) $ 76,277 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Cash Flows Year Ended December 31, 2017 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Operating activities: Net income (loss) $ 199,589 $ 159,462 $ 99,820 $ (259,282 ) $ 199,589 Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities: Equity in earnings of subsidiaries (259,282 ) — — 259,282 — Depreciation and amortization — 66,482 76,528 — 143,010 Amortization of debt issuance costs 10,270 — (415 ) — 9,855 Equity-based compensation expense 23,467 — — — 23,467 Deferred income tax expense 1,236 28,882 1,254 — 31,372 Debt extinguishment costs 810 — — — 810 Other 4,189 2,498 4,725 — 11,412 Change in operating assets and liabilities, net of effect of acquisitions: Accounts receivable, net — (21,791 ) (6,779 ) — (28,570 ) Other current assets — (6,429 ) 27,237 — 20,808 Other assets 24,549 (3,277 ) 101 (24,549 ) (3,176 ) Accounts payable and other accrued liabilities — 4,909 (15,022 ) — (10,113 ) Accrued salaries and benefits — (3,974 ) (5,014 ) — (8,988 ) Other liabilities — 8,794 3,000 — 11,794 Net cash provided by (used in) continuing operating activities 4,828 235,556 185,435 (24,549 ) 401,270 Net cash used in discontinued operating activities — (1,693 ) — — (1,693 ) Net cash provided by (used in) operating activities 4,828 233,863 185,435 (24,549 ) 399,577 Investing activities: Cash paid for acquisitions, net of cash acquired — — (18,191 ) — (18,191 ) Cash paid for capital expenditures — (161,312 ) (112,865 ) — (274,177 ) Cash paid for real estate acquisitions — (37,047 ) (4,010 ) — (41,057 ) Other — (7,944 ) 4,843 — (3,101 ) Net cash used in investing activities — (206,303 ) (130,223 ) — (336,526 ) Financing activities: Principal payments on long-term debt (34,550 ) (14,250 ) (10,554 ) 24,549 (34,805 ) Repayment of long-term debt (22,500 ) — — — (22,500 ) Common stock withheld for minimum statutory taxes, net (3,455 ) — — — (3,455 ) Other (539 ) 1,225 — — 686 Cash provided by (used in) intercompany activity 56,216 16,644 (72,860 ) — — Net cash (used in) provided by financing activities (4,828 ) 3,619 (83,414 ) 24,549 (60,074 ) Effect of exchange rate changes on cash — — 7,250 — 7,250 Net increase in cash and cash equivalents — 31,179 (20,952 ) — 10,227 Cash and cash equivalents at beginning of the period — 15,681 41,382 — 57,063 Cash and cash equivalents at end of the period $ — $ 46,860 $ 20,430 $ — $ 67,290 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Cash Flows Year Ended December 31, 2016 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Operating activities: Net income (loss) $ 4,176 $ 117,973 $ (52,413 ) $ (65,560 ) $ 4,176 Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities: Equity in earnings of subsidiaries (65,560 ) — — 65,560 — Depreciation and amortization — 58,018 77,085 — 135,103 Amortization of debt issuance costs 10,751 — (427 ) — 10,324 Equity-based compensation expense 28,345 — — — 28,345 Deferred income tax (benefit) expense (2,172 ) 50,611 (19,792 ) — 28,647 Loss from discontinued operations, net of taxes — — — — — Debt extinguishment costs 4,253 — — — 4,253 Loss on divestiture — 778 178,031 — 178,809 (Gain) loss on foreign currency derivatives (523 ) — — — (523 ) Other — 4,022 693 — 4,715 Change in operating assets and liabilities, net of effect of acquisitions: Accounts receivable, net — (24,017 ) 8,299 — (15,718 ) Other current assets — (3,138 ) (17,510 ) — (20,648 ) Other assets (3,109 ) (4,048 ) (306 ) 3,109 (4,354 ) Accounts payable and other accrued liabilities — (45,552 ) 68,245 — 22,693 Accrued salaries and benefits — 3,844 (12,416 ) — (8,572 ) Other liabilities — 4,050 434 — 4,484 Net cash (used in) provided by continuing operating activities (23,839 ) 162,541 229,923 3,109 371,734 Net cash used in discontinued operating activities — (10,256 ) — — (10,256 ) Net cash (used in) provided by operating activities (23,839 ) 152,285 229,923 3,109 361,478 Investing activities: Cash paid for acquisitions, net of cash acquired — (103,359 ) (580,096 ) — (683,455 ) Cash paid for capital expenditures — (177,593 ) (129,879 ) — (307,472 ) Cash paid for real estate acquisitions — (28,956 ) (11,801 ) — (40,757 ) Settlement of foreign currency derivatives — 523 — — 523 Cash received for divestiture 370,000 7,859 (4,593 ) — 373,266 Other — (1,573 ) (897 ) — (2,470 ) Net cash used in investing activities 370,000 (303,099 ) (727,266 ) — (660,365 ) Financing activities: Borrowings on long-term debt 1,480,000 — — — 1,480,000 Borrowings on revolving credit facility 179,000 — — — 179,000 Principal payments on revolving credit facility (337,000 ) — — — (337,000 ) Principal payments on long-term debt (49,706 ) (293,000 ) (3,344 ) 296,109 (49,941 ) Repayment of assumed debt (1,348,389 ) — — — (1,348,389 ) Repayment of long-term debt (200,594 ) — — — (200,594 ) Payment of debt issuance costs (36,649 ) — — — (36,649 ) Issuance of common stock 685,097 — — — 685,097 Common stock withheld for minimum statutory taxes, net (8,846 ) — — — (8,846 ) Other (1,149 ) (2,688 ) — — (3,837 ) Cash (used in) provided by intercompany activity (707,925 ) 460,196 546,947 (299,218 ) — Net cash provided by (used in) financing activities (346,161 ) 164,508 543,603 (3,109 ) 358,841 Effect of exchange rate changes on cash — — (14,106 ) — (14,106 ) Net increase in cash and cash equivalents — 13,694 32,154 — 45,848 Cash and cash equivalents at beginning of the period — 1,987 9,228 — 11,215 Cash and cash equivalents at end of the period $ — $ 15,681 $ 41,382 $ — $ 57,063 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Cash Flows Year Ended December 31, 2015 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Operating activities: Net income (loss) $ 111,476 $ 138,764 $ 37,414 $ (176,178 ) $ 111,476 Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities: Equity in earnings of subsidiaries (176,178 ) — — 176,178 — Depreciation and amortization — 41,768 21,782 — 63,550 Amortization of debt issuance costs 7,147 — (438 ) — 6,709 Equity-based compensation expense 20,472 — — — 20,472 Deferred income tax (benefit) expense 617 42,246 750 — 43,613 Loss from discontinued operations, net of taxes — (111 ) — — (111 ) Debt extinguishment costs 10,818 — — — 10,818 Loss (gain) on foreign currency derivatives 1,926 — — — 1,926 Other — 1,582 33 — 1,615 Change in operating assets and liabilities, net of effect of acquisitions: Accounts receivable, net — (18,632 ) (6,322 ) — (24,954 ) Other current assets — (1,152 ) (1,565 ) — (2,717 ) Other assets (1,100 ) (8,567 ) 546 1,100 (8,021 ) Accounts payable and other accrued liabilities — (7,583 ) 14,451 — 6,868 Accrued salaries and benefits — 312 1,346 — 1,658 Other liabilities — 9,350 (114 ) — 9,236 Net cash (used in) provided by continuing operating activities (24,822 ) 197,977 67,883 1,100 242,138 Net cash provided by discontinued operating activities — (1,735 ) — — (1,735 ) Net cash (used in) provided by operating activities (24,822 ) 196,242 67,883 1,100 240,403 Investing activities: Cash paid for acquisitions, net of cash acquired — (254,848 ) (319,929 ) — (574,777 ) Cash paid for capital expenditures — (172,329 ) (103,718 ) — (276,047 ) Cash paid for real estate acquisitions — (25,293 ) (1,329 ) — (26,622 ) Settlement of foreign currency derivatives — (1,926 ) — — (1,926 ) Other — (5,099 ) — — (5,099 ) Net cash used in investing activities — (459,495 ) (424,976 ) — (884,471 ) Financing activities: Borrowings on long-term debt 1,150,000 — — — 1,150,000 Borrowings on revolving credit facility 468,000 — — — 468,000 Principal payments on revolving credit facility (310,000 ) — — — (310,000 ) Principal payments on long-term debt (31,965 ) — (1,315 ) 1,315 (31,965 ) Repayment of assumed debt (904,467 ) — — — (904,467 ) Repayment of long-term debt (97,500 ) — — — (97,500 ) Payment of debt issuance costs (26,421 ) — — — (26,421 ) Payment of premium on senior notes (7,480 ) — — — (7,480 ) Issuance of common stock, net 331,308 — — — 331,308 Common stock withheld for minimum statutory taxes, net (7,762 ) — — — (7,762 ) Excess tax benefit from equity awards 309 — — — 309 Other — (420 ) — — (420 ) Cash (used in) provided by intercompany activity (539,200 ) 191,334 350,281 (2,415 ) — Net cash provided by (used in) financing activities 24,822 190,914 348,966 (1,100 ) 563,602 Effect of exchange rate changes on cash — (2,359 ) — — (2,359 ) Net (decrease) increase in cash and cash equivalents — (74,698 ) (8,127 ) — (82,825 ) Cash and cash equivalents at beginning of the period — 76,685 17,355 — 94,040 Cash and cash equivalents at end of the period $ — $ 1,987 $ 9,228 $ — $ 11,215

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, cash and cash equivalent balances may exceed federally insured limits. Management believes that the Company mitigates any risks by depositing cash and investing in cash equivalents with major financial institutions.
Revenue and Accounts Receivable	Revenue and Accounts Receivable Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. The Company receives payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; (iv) public funded sources in the U.K. (including the NHS, Clinical Commissioning Groups (“CCGs”) and local authorities in England, Scotland and Wales); and (v) individual patients and clients. Revenue is recorded in the period in which services are provided at established billing rates less contractual adjustments based on amounts reimbursable by Medicare or Medicaid under provisions of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates. The following table presents the percentage of revenue before provision for doubtful accounts generated by each payor type: Year Ended December 31, 2017 2016 2015 Commercial 19.8 % 18.7 % 23.1 % Medicare 9.8 9.4 11.7 Medicaid 27.7 25.4 33.3 U.K. public funded sources 32.6 35.8 19.5 Self-Pay 8.7 9.4 9.6 Other 1.4 1.3 2.8 Revenue before provision for doubtful accounts 100 % 100 % 100 % On a combined basis, revenue related to the Medicare and Medicaid programs were 38%, 35% and 45% of all revenue before provision for doubtful accounts for the years ended December 31, 2017, 2016 and 2015, respectively. The Company’s concentration of credit risk from other payors is reduced by the large number of payors and their geographic dispersion. The Company generated approximately 36%, 38% and 20% of its revenue for the years ended December 31, 2017, 2016 and 2015, respectively, from facilities located in the U.K.
Allowance for Contractual Discounts	Allowance for Contractual Discounts The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the allowance for contractual discounts on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management. Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s cost report receivables were $9.0 million and $7.4 million at December 31, 2017 and 2016, respectively, and were included in other current assets in the consolidated balance sheets. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount. The net adjustments to estimated cost report settlements resulted in increases to revenue of $0.2 million, $0.7 million and $1.9 million for the years ended December 31, 2017, 2016 and 2015, respectively. Management believes that we are in substantial compliance with all applicable laws and regulations and is not aware of any material pending or threatened investigations involving allegations of wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties and exclusion from the Medicare and Medicaid programs.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company’s ability to collect outstanding patient receivables from third-party payors is critical to its operating performance and cash flows. The primary collection risk with regard to patient receivables relates to uninsured patient accounts or patient accounts for which primary insurance has paid, but the portion owed by the patient remains outstanding. The Company estimates uncollectible accounts and establishes an allowance for doubtful accounts in order to adjust accounts receivable to estimated net realizable value. In evaluating the collectability of accounts receivable, the Company considers a number of factors, including the age of the accounts, historical collection experience, current economic conditions, and other relevant factors. Accounts receivable that are determined to be uncollectible based on the Company’s policies are written off to the allowance for doubtful accounts. Significant changes in payor mix or business office operations could have a significant impact on the Company’s results of operations and cash flows. A summary of activity in the Company’s allowance for doubtful accounts is as follows (in thousands): Balance at Beginning of Period Additions Charged to Costs and Expenses Accounts Written Off, Net of Recoveries Balance at End of Period Year ended December 31, 2015 $ 22,449 $ 35,127 $ (28,244 ) $ 29,332 Year ended December 31, 2016 29,332 41,909 (32,325 ) 38,916 Year ended December 31, 2017 38,916 40,918 (40,031 ) 39,803
Charity Care	Charity Care The Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive based on Company policies and federal and state poverty thresholds. The costs of providing charity care services were $6.6 million, $7.1 million and $4.6 million for the years ended December 31, 2017, 2016 and 2015, respectively. The estimated cost of charity care services was determined using a ratio of cost to gross charges determined from our most recently filed Medicare cost reports and applying that ratio to the gross charges associated with providing charity care for the period.
Insurance	Insurance The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company’s professional liability risk is insured through a wholly-owned insurance subsidiary. The Company’s wholly-owned insurance subsidiary insures the Company for professional liability losses up to $78.0 million in the aggregate. The insurance subsidiary has obtained reinsurance with unrelated commercial insurers for professional liability risks of $75.0 million in excess of a retention level of $3.0 million. The reserve for professional and general liability risks was estimated based on historical claims, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. The professional and general liability reserve was $55.0 million as of December 31, 2017, of which $22.8 million was included in other accrued liabilities and $32.2 million was included in other long-term liabilities. The professional and general liability reserve was $52.3 million as of December 31, 2016, of which $11.7 million was included in other accrued liabilities and $40.6 million was included in other long-term liabilities. The Company estimates receivables for the portion of professional and general liability reserves that are recoverable under the Company’s insurance policies. Such receivable was $22.7 million as of December 31, 2017, of which $17.6 million was included in other current assets and $5.1 million was included in other assets, and such receivable was $25.9 million as of December 31, 2016, of which $6.5 million was included in other current assets and $19.4 million was included in other assets. The Company’s statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $18.5 million as of December 31, 2017, of which $10.0 million was included in accrued salaries and benefits and $8.5 million was included in other long-term liabilities, and such liability was $16.6 million as of December 31, 2016, of which $10.0 million was included in accrued salaries and benefits and $6.6 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures.
Property and Equipment and Other Long-Lived Assets	Property and Equipment and Other Long-Lived Assets Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $143.0 million, $134.8 million and $63.0 million for the years ended December 31, 2017, 2016 and 2015, respectively. The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful lives, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows.
Goodwill and Indefinite-Lived Intangible Assets	Goodwill and Indefinite-Lived Intangible Assets The Company’s goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate that the carrying value of a reporting unit may not be recoverable. The Company has two operating segments, U.S. Facilities and U.K. Facilities, for segment reporting purposes, each of which represents a reporting unit for purposes of the Company’s goodwill impairment test. Potential impairment is noted for a reporting unit if its carrying value exceeds the fair value of the reporting unit. For a reporting unit with potential impairment of goodwill, the Company determines the implied fair value of goodwill. If the carrying value of goodwill exceeds its implied fair value, an impairment loss is recorded. The Company’s annual impairment tests of goodwill and other indefinite-lived intangibles in 2017, 2016 and 2015 resulted in no impairment charges.
Other Current Assets	Other Current Assets Other current assets consisted of the following (in thousands): As of December 31, 2017 2016 Other receivables $ 30,455 $ 44,975 Prepaid expenses 27,320 27,455 Insurance receivable – current portion 17,588 6,472 Income taxes receivable 15,056 11,714 Workers’ compensation deposits – current portion 10,000 10,000 Inventory 4,787 4,633 Other 2,129 2,288 Other current assets $ 107,335 $ 107,537
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): As of December 31, 2017 2016 Accrued expenses $ 37,268 $ 37,323 Accrued interest 36,370 33,616 Unearned income 31,342 28,805 Insurance liability – current portion 22,788 11,672 Accrued property taxes 3,945 2,732 Income taxes payable 1,012 527 Other 8,488 8,283 Other accrued liabilities $ 141,213 $ 122,958
Stock Compensation	Stock Compensation The Company measures and recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, “ Compensation—Stock Compensation
Earnings Per Share	Earnings Per Share Basic and diluted earnings per share are calculated in accordance with FASB ASC 260, “ Earnings Per Share non-vested
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date. The Company reviews its deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The Tax Act was enacted on December 22, 2017. The Tax Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities” 2017-12”). 2017-12 2017-12 2017-12 In January 2017, the FASB issued ASU 2017-04, “Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” 2017-04”). 2017-04 2017-04 2017-04 In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” 2016-09”). 2016-09 2016-09 2016-09 In March 2016, the FASB issued ASU 2016-02, “Leases” 2016-02”). 2016-02’s 2016-02 2016-02 right-of-use 2016-02 In May 2014, the FASB and the International Accounting Standards Board issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” 2014-09”). 2014-09’s 2014-09 Step 1: Identify the contract with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 ASU 2014-09 2014-09 2014-09 The Company will adopt ASU 2014-09 2014-09, 2014-09

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Percentage of Revenue before Provision for Doubtful Accounts Generated by Each Payor Type	The following table presents the percentage of revenue before provision for doubtful accounts generated by each payor type: Year Ended December 31, 2017 2016 2015 Commercial 19.8 % 18.7 % 23.1 % Medicare 9.8 9.4 11.7 Medicaid 27.7 25.4 33.3 U.K. public funded sources 32.6 35.8 19.5 Self-Pay 8.7 9.4 9.6 Other 1.4 1.3 2.8 Revenue before provision for doubtful accounts 100 % 100 % 100 %
Summary of Activity in the Company's Allowance for Doubtful Accounts	A summary of activity in the Company’s allowance for doubtful accounts is as follows (in thousands): Balance at Beginning of Period Additions Charged to Costs and Expenses Accounts Written Off, Net of Recoveries Balance at End of Period Year ended December 31, 2015 $ 22,449 $ 35,127 $ (28,244 ) $ 29,332 Year ended December 31, 2016 29,332 41,909 (32,325 ) 38,916 Year ended December 31, 2017 38,916 40,918 (40,031 ) 39,803
Other Current Assets	Other current assets consisted of the following (in thousands): As of December 31, 2017 2016 Other receivables $ 30,455 $ 44,975 Prepaid expenses 27,320 27,455 Insurance receivable – current portion 17,588 6,472 Income taxes receivable 15,056 11,714 Workers’ compensation deposits – current portion 10,000 10,000 Inventory 4,787 4,633 Other 2,129 2,288 Other current assets $ 107,335 $ 107,537
Summary of Other Accrued Liabilities	Other accrued liabilities consisted of the following (in thousands): As of December 31, 2017 2016 Accrued expenses $ 37,268 $ 37,323 Accrued interest 36,370 33,616 Unearned income 31,342 28,805 Insurance liability – current portion 22,788 11,672 Accrued property taxes 3,945 2,732 Income taxes payable 1,012 527 Other 8,488 8,283 Other accrued liabilities $ 141,213 $ 122,958

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 (in thousands except per share amounts): Year Ended December 31, 2017 2016 2015 Numerator: Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.: Income from continuing operations $ 199,835 $ 6,143 $ 112,443 Income from discontinued operations — — 111 Net income attributable to Acadia Healthcare Company, Inc. $ 199,835 $ 6,143 $ 112,554 Denominator: Weighted average shares outstanding for basic earnings per share 86,948 85,701 68,085 Effects of dilutive instruments 112 271 306 Shares used in computing diluted earnings per common share 87,060 85,972 68,391 Basic earnings per share attributable to Acadia Healthcare Company, Inc.: Income from continuing operations $ 2.30 $ 0.07 $ 1.65 Income from discontinued operations — — — Net income attributable to Acadia Healthcare Company, Inc.: $ 2.30 $ 0.07 $ 1.65

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2017
Transaction Related Expenses as Incurred	Transaction-related expenses comprised the following costs for the years ended December 31, 2017, 2016 and 2015 (in thousands): Year Ended December 31, 2017 2016 2015 Severance and contract termination costs $ 14,709 $ 12,415 $ 8,466 Legal, accounting and other fees 9,558 21,058 17,768 Advisory and financing commitment fees — 14,850 10,337 $24,267 $48,323 $36,571
Priory, Serenity Knolls, TrustPoint and Pocono Mountain Acquisitions [Member]
Summary of Acquisitions	The fair values assigned to certain assets and liabilities assumed, at the date of acquisition dates, during the year ended December 31, 2016 in connection with Priory, Serenity Knolls, Trustpoint and Pocono Mountain acquisitions (collectively the “2016 Acquisitions”) were as follows (in thousands): Priory Other Total Cash $ 10,253 $ 2,488 $ 12,741 Accounts receivable 57,832 4,264 62,096 Prepaid expenses and other current assets 7,921 103 8,024 Property and equipment 1,598,156 35,400 1,633,556 Goodwill 679,265 96,052 775,317 Intangible assets 23,200 338 23,538 Other assets 8,862 47 8,909 Total assets acquired 2,385,489 138,692 2,524,181 Accounts payable 24,203 749 24,952 Accrued salaries and benefits 39,588 918 40,506 Other accrued expenses 48,305 391 48,696 Deferred tax liabilities – noncurrent 56,462 269 56,731 Debt 1,348,389 — 1,348,389 Other liabilities 61,311 30,243 91,554 Total liabilities assumed 1,578,258 32,570 1,610,828 Net assets acquired $ 807,231 $ 106,122 $ 913,353

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Other Identifiable Intangible Assets and Related Accumulated Amortization	Other identifiable intangible assets and related accumulated amortization consisted of the following as of December 31, 2017 and 2016 (in thousands): Gross Carrying Amount Accumulated Amortization December 31, 2017 December 31, 2016 December 31, 2017 December 31, 2016 Intangible assets subject to amortization: Contract intangible assets $ 2,100 $ 2,100 $ (2,100 ) $ (2,100 ) Non-compete 1,147 1,147 (1,147 ) (1,147 ) 3,247 3,247 (3,247 ) (3,247 ) Intangible assets not subject to amortization: Licenses and accreditations 12,266 12,228 — — Trade names 60,586 57,538 — — Certificates of need 14,496 13,544 — — 87,348 83,310 — — Total $ 90,595 $ 86,557 $ (3,247 ) $ (3,247 )

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Components of Long-Term Debt	Long-term debt consisted of the following (in thousands): December 31, 2017 December 31, 2016 Amended and Restated Senior Credit Facility: Senior Secured Term A Loans $ 380,000 $ 400,000 Senior Secured Term B Loans 1,398,400 1,435,450 Senior Secured Revolving Line of Credit — — 6.125% Senior Notes due 2021 150,000 150,000 5.125% Senior Notes due 2022 300,000 300,000 5.625% Senior Notes due 2023 650,000 650,000 6.500% Senior Notes due 2024 390,000 390,000 9.0% and 9.5% Revenue Bonds 21,920 22,175 Less: unamortized debt issuance costs, discount and premium (50,432 ) (59,816 ) 3,239,888 3,287,809 Less: current portion (34,830 ) (34,805 ) Long-term debt $ 3,205,058 $ 3,253,004
Summary of Aggregate Maturities of Long-Term Debt	The aggregate maturities of long-term debt as of December 31, 2017 were as follows (in thousands): 2018 $ 34,830 2019 34,855 2020 44,880 2021 474,910 2022 767,240 Thereafter 1,933,605 Total $ 3,290,320

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Activity	Stock option activity during 2016 and 2017 was as follows (aggregate intrinsic value in thousands): Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Options outstanding at January 1, 2016 694,743 $ 42.87 7.70 $ 20,717 Options granted 503,850 57.98 9.28 297 Options exercised (57,397 ) 31.92 N/A 1,530 Options cancelled (140,250 ) 57.13 N/A N/A Options outstanding at December 31, 2016 1,000,946 49.42 7.80 8,166 Options granted 259,300 42.25 9.30 205 Options exercised (87,367 ) 25.92 N/A 1,636 Options cancelled (198,313 ) 54.71 N/A N/A Options outstanding at December 31, 2017 974,566 $ 47.89 7.46 $ 3,802 Options exercisable at December 31, 2016 288,959 $ 42.81 6.22 $ 6,111 Options exercisable at December 31, 2017 405,634 $ 41.20 6.05 $ 3,549
Restricted Stock Activity	Restricted stock activity during 2016 and 2017 was as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2016 944,562 $ 52.74 Granted 387,347 55.38 Cancelled (122,178 ) 57.02 Vested (365,312 ) 47.18 Unvested at December 31, 2016 844,419 $ 55.76 Granted 404,224 42.38 Cancelled (145,981 ) 55.03 Vested (292,794 ) 53.07 Unvested at December 31, 2017 809,868 $ 50.19
Restricted Stock Unit Activity	Restricted stock unit activity during 2016 and 2017 was as follows: Number of Units Weighted Average Grant-Date Fair Value Unvested at January 1, 2016 218,084 $ 56.97 Granted 230,750 56.95 Cancelled — — Vested (175,235 ) 52.71 Unvested at December 31, 2016 273,599 $ 59.68 Granted 219,840 43.23 Cancelled — — Vested (132,530 ) 58.67 Unvested at December 31, 2017 360,909 $ 50.04
Schedule of Stock Options Valuation Assumptions	The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2017 and 2016: December 31, 2017 December 31, 2016 Weighted average grant-date fair value of options $ 14.39 $ 18.96 Risk-free interest rate 2.0 % 1.4 % Expected volatility 33 % 33 % Expected life (in years) 5.5 5.5

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Components of Provision for Income Taxes	Income tax expense (benefit) from continuing operations consists of the following for the periods presented (in thousands): Year Ended December 31, 2017 2016 2015 Current: Federal $ 3,325 $ 572 $ (218 ) State 680 (863 ) 4,078 Foreign 1,832 423 5,915 Total current 5,837 132 9,775 Deferred: Federal 27,179 45,077 40,635 State 4,408 1,491 5,349 Foreign (215 ) (17,921 ) (2,371 ) Total deferred provision 31,372 28,647 43,613 Provision for income taxes $ 37,209 $ 28,779 $ 53,388
Effective Income Tax Rate	A reconciliation of the U.S. federal statutory rate, from continuing operations, to the effective tax rate is as follows for the periods presented: Year Ended December 31, 2017 2016 2015 U.S. federal statutory rate on income before income taxes 35.0 % 35.0 % 35.0 % Impact of foreign operations (14.1 ) (13.5 ) (10.0 ) Impact of foreign divestiture — 39.2 — Effects of statutory rate change (8.5 ) (14.5 ) — State income taxes, net of federal tax effect 2.1 7.5 4.8 Permanent differences 1.8 8.3 4.2 Transaction related items — 25.9 — Change in valuation allowance 1.6 2.8 1.2 Unrecognized tax benefit release (0.8 ) (7.2 ) — Other (1.4 ) 3.8 (2.8 ) Effective income tax rate 15.7 % 87.3 % 32.4 %
Summary of Domestic and Foreign Components of Income (Loss) from Continuing Operations before Income Taxes	The domestic and foreign components of income (loss) from continuing operations before income taxes are as follows (in thousands): Year Ended December 31, 2017 2016 2015 Foreign $ 120,905 $ (144,717 ) $ 28,316 Domestic 115,893 177,672 136,437 Total $ 236,798 $ 32,955 $ 164,753
Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities of the Company at December 31, 2017 and December 31, 2016 were as follows (in thousands): December 31, 2017 2016 Deferred tax assets: Net operating losses and tax credit carryforwards – federal and state $ 29,409 $ 37,638 Bad debt allowance 827 15,381 Accrued compensation and severance 14,179 23,379 Pension reserves 1,494 697 Insurance reserves 13,483 17,468 Leases 5,332 2,926 Accrued expenses 3,114 — Interest carryforwards 5,074 — Other assets 1,747 2,038 Total gross deferred tax assets 74,659 99,527 Less: valuation allowance (21,155 ) (16,031 ) Deferred tax assets 53,504 83,496 Deferred tax liabilities: Fixed asset basis difference (54,214 ) (45,510 ) Prepaid items (1,490 ) (1,324 ) Intangible assets (70,820 ) (77,655 ) Accrued expenses — (4,531 ) Other liabilities (3,582 ) (29,216 ) Total deferred tax liabilities (130,106 ) (158,236 ) Total net deferred tax liability $ (76,602 ) $ (74,740 )
Unrecognized Income Tax Benefits Net of Federal Benefit	A reconciliation of the beginning and ending amount of unrecognized income tax benefits net of the federal benefit is as follows (in thousands): 2017 2016 2015 Balance at January 1 $ 6,949 $ 4,511 $ 2,923 Additions based on tax positions related to the current year 5,488 — 1,516 Additions for tax positions of prior years 95 5,427 2,874 Reductions as a result of the lapse of applicable statutes of limitations (6,428 ) (2,989 ) (2,802 ) Balance at December 31 $ 6,104 $ 6,949 $ 4,511

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities	The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 9.0% and 9.5% Revenue Bonds, derivative instruments and contingent consideration liability as of December 31, 2017 and 2016 were as follows (in thousands): Carrying Amount Fair Value December 31, December 31, 2017 2016 2017 2016 Amended and Restated Senior Credit Facility $ 1,749,185 $ 1,799,993 $ 1,749,185 $ 1,799,993 6.125% Senior Notes due 2021 $ 148,098 $ 147,574 $ 150,134 $ 152,186 5.125% Senior Notes due 2022 $ 296,174 $ 295,442 $ 296,914 $ 293,595 5.625% Senior Notes due 2023 $ 641,891 $ 640,574 $ 651,519 $ 640,574 6.500% Senior Notes due 2024 $ 382,251 $ 381,268 $ 397,541 $ 389,847 9.0% and 9.5% Revenue Bonds $ 22,289 $ 22,959 $ 22,289 $ 22,959 Derivative instruments $ 12,997 $ 73,509 $ 12,997 $ 73,509 Contingent consideration liabilities $ — $ 107 $ — $ 107

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2017
Leases [Abstract]
Schedule of Aggregate Minimum Lease Payments under Non-cancelable Operating Leases	Aggregate minimum lease payments under non-cancelable 2018 $ 69,613 2019 64,556 2020 60,156 2021 56,620 2022 51,071 Thereafter 835,369 Total minimum rental obligations $ 1,137,385

Noncontrolling Interests (Table

Noncontrolling Interests (Tables)	12 Months Ended
	Dec. 31, 2017
Noncontrolling Interest [Abstract]
Summary of Redeemable Noncontrolling Interests	The components of redeemable noncontrolling interests are as follows (in thousands): Balance at January 1, 2016 $ 8,055 Acquisition of redeemable noncontrolling interests 11,666 Net loss attributable to noncontrolling interests (1,967 ) Balance at December 31, 2016 17,754 Acquisition of redeemable noncontrolling interests 4,909 Net loss attributable to noncontrolling interests (246 ) Balance at December 31, 2017 $ 22,417

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2017
Summary of Reconciliation of Segment EBITDA to Income from Continuing Operations	The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands): Year Ended December 31, 2017 2016 2015 Revenue: U.S. Facilities $ 1,809,844 $ 1,698,525 $ 1,426,205 U.K. Facilities 1,026,472 1,110,361 360,698 Corporate and Other — 2,028 7,589 $ 2,836,316 $ 2,810,914 $ 1,794,492 Segment EBITDA (1) U.S. Facilities $ 475,260 $ 443,341 $ 377,587 U.K. Facilities 198,566 245,046 90,035 Corporate and Other (69,467 ) (79,797 ) (62,790 ) $ 604,359 $ 608,590 $ 404,832 Year Ended December 31, 2017 2016 2015 Segment EBITDA(1) $ 604,359 $ 608,590 $ 404,832 Plus (less): Equity-based compensation expense (23,467 ) (28,345 ) (20,472 ) Debt extinguishment costs (810 ) (4,253 ) (10,818 ) Loss on divestiture — (178,809 ) — Gain (loss) on foreign currency derivatives — 523 (1,926 ) Transaction-related expenses (24,267 ) (48,323 ) (36,571 ) Interest expense, net (176,007 ) (181,325 ) (106,742 ) Depreciation and amortization (143,010 ) (135,103 ) (63,550 ) Income from continuing operations before income taxes $ 236,798 $ 32,955 $ 164,753
Summary of Assets by Operating Segment	December 31, 2017 2016 Assets (2) U.S. Facilities $ 3,567,126 $ 3,382,167 U.K. Facilities 2,647,150 2,441,018 Corporate and Other 210,226 201,541 $ 6,424,502 $ 6,024,726 (1) Segment EBITDA is defined as income from continuing operations before provision for income taxes, equity-based compensation expense, debt extinguishment costs, gain on foreign currency derivatives, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. (2) Assets include property and equipment for the U.S. Facilities of $1.2 billion, U.K. Facilities of $1.8 billion and corporate and other of $49.2 million at December 31, 2017. Assets include property and equipment for the U.S. Facilities of $1.0 billion, U.K. Facilities of $1.7 billion and corporate and other of $27.1 million at December 31, 2016.
Goodwill [Member]
Summary of Assets by Operating Segment	U.S. Facilities U.K. Facilities Corporate and Other Consolidated Goodwill: Balance at January 1, 2017 $ 2,041,795 $ 639,393 $ — $ 2,681,188 Increase from 2017 acquisition — 15,302 — 15,302 Foreign currency translation — 60,770 — 60,770 Purchase price allocation and other 797 (6,883 ) — (6,086 ) Balance at December 31, 2017 $ 2,042,592 $ 708,582 $ — $ 2,751,174

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Summary of Funded Status (Unfunded Liability) of Partnerships in Care Pension Plan Based Upon Actuarial Valuations	The following table summarizes the funded status (unfunded liability) of the Partnerships in Care Pension Plan based upon actuarial valuations prepared as of December 31, 2017 and 2016 (in thousands): 2017 2016 Projected benefit obligation $ 67,288 $ 64,162 Fair value of plan assets 58,493 53,462 Unfunded liability $ 8,795 $ 10,700
Summary of Changes in Partnerships in Care Pension Plan Net Pension Liability	The following table summarizes changes in the Partnerships in Care Pension Plan net pension liability as of December 31, 2017 and 2016 (in thousands): 2017 2016 Net pension liability at beginning of period $ 10,700 $ 2,821 Employer contributions (809 ) (740 ) Net pension expense (benefit) 426 339 Pension liability adjustment (2,544 ) 8,781 Foreign currency translation gain (loss) 1,022 (501 ) Net pension liability at end of period $ 8,795 $ 10,700
Summary of Assumptions Used to Determine Plan Benefit obligation	A pension liability of $8.8 million and $10.7 million were recorded within other liabilities on the consolidated balance sheets as of December 31, 2017 and 2016. The following assumptions were used to determine the plan benefit obligation: Discount rate 2.5 % 2.7 % Compensation increase rate 2.3 % 2.4 % Measurement date December 31, 2017 December 31, 2016 Assumptions used to determine the net periodic pension plan expense for the year ended December 31, 2017 and 2016 were as follows: 2017 2016 Discount rate 2.5 % 2.7 % Expected long-term rate of return on plan assets 2.5 % 2.7 %
Summary of Components of Net Pension Plan Expense	A summary of the components of net pension plan expense for the year ended December 31, 2017 and 2016 is as follows (in thousands): 2017 2016 Interest cost on projected benefit obligation $ 1,738 $ 1,964 Expected return on assets (1,312 ) (1,625 ) Total pension plan expense (benefit) $ 426 $ 339
Schedule of Weighted-Average Asset Allocation by Asset Category in Partnerships in Care Pension Plan	The Partnerships in Care Pension Plan’s weighted-average asset allocations by asset category as of December 31, 2017 and 2016 were as follows: December 31, 2017 December 31, 2016 Cash and cash equivalents 0.7 % 1.5 % U.K. government obligation 19.0 % 14.5 % Annuity contracts 38.6 % 41.6 % Equity securities 29.4 % 26.3 % Debt securities 9.9 % 12.1 % Other 2.4 % 4.0 %

Other Comprehensive Loss (Table

Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Components Of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss are as follows (in thousands): Foreign Currency Translation Adjustments Change in Fair Value of Derivative Instruments Pension Plan Total Balance at January 1, 2015 $ (66,206 ) $ — $ (2,164 ) $ (68,370 ) Foreign currency translation loss (40,103 ) — — (40,103 ) Pension liability adjustment, net of tax of $0.9 million — — 3,826 3,826 Balance at December 31, 2015 (106,309 ) — 1,662 (104,647 ) Foreign currency translation loss (477,772 ) — — (477,772 ) Gain on derivative instruments, net of tax of $29.1 million — 40,598 — 40,598 Pension liability adjustment, net of tax of $(1.3) million — — (7,749 ) (7,749 ) Balance at December 31, 2016 (584,081 ) 40,598 (6,087 ) (549,570 ) Foreign currency translation gain 207,341 — — 207,341 Loss on derivative instruments, net of tax of $(22.9) million — (33,431 ) — (33,431 ) Pension liability adjustment, net of tax of $0.4 million — — 1,542 1,542 Balance at December 31, 2017 $ (376,740 ) $ 7,167 $ (4,545 ) $ (374,118 )

Quarterly Information (Unaudi43

Quarterly Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Quarter Ended March 31, June 30, September 30, December 31, (In thousands except per share amounts) 2017: Revenue $ 679,194 $ 715,896 $ 716,714 $ 724,512 Income from continuing operations before income taxes $ 48,484 $ 66,216 $ 61,459 $ 60,639 Net income attributable to Acadia Healthcare Company, Inc. stockholders $ 34,958 $ 49,630 $ 45,618 $ 69,629 (1) Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders $ 0.40 $ 0.57 $ 0.52 $ 0.80 (1) Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders $ 0.40 $ 0.57 $ 0.52 $ 0.80 (1) 2016: Revenue $ 616,813 $ 756,548 $ 734,665 $ 702,888 Income from continuing operations before income taxes $ 32,479 $ 73,852 $ (115,814 ) (2) $ 42,438 (3) Net income attributable to Acadia Healthcare Company, Inc. stockholders $ 25,688 $ 56,445 $ (117,808 ) (2) $ 41,818 (3) Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders $ 0.31 $ 0.65 $ (1.36 ) (2) $ 0.48 (3) Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders $ 0.31 $ 0.65 $ (1.36 ) (2) $ 0.48 (3) (1) Includes a one-time (2) Includes loss on divestiture of $174.7 million and debt extinguishment costs of $3.4 million, or $142.0 million net of taxes, in connection with the U.K. Divestiture and the repricing of our Tranche B-2 (3) Includes loss on divestiture of $4.0 million and debt extinguishment costs of $0.8 million, or $3.1 million net of taxes, in connection with the Company’s divestitures and the Refinancing Amendment.

Financial Information for the44

Financial Information for the Company and Its Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Condensed Consolidating Balance Sheets	Acadia Healthcare Company, Inc. Condensed Consolidating Balance Sheets December 31, 2017 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Current assets: Cash and cash equivalents $ — $ 46,860 $ 20,430 $ — $ 67,290 Accounts receivable, net — 230,890 66,035 — 296,925 Other current assets — 85,746 21,589 — 107,335 Total current assets — 363,496 108,054 — 471,550 Property and equipment, net — 1,086,802 1,961,328 — 3,048,130 Goodwill — 1,936,057 815,117 — 2,751,174 Intangible assets, net — 57,628 29,720 — 87,348 Deferred tax assets – noncurrent 2,370 — 3,731 (2,370 ) 3,731 Derivative instruments 12,997 — — — 12,997 Investment in subsidiaries 5,429,386 — — (5,429,386 ) — Other assets 381,913 38,860 7,807 (379,008 ) 49,572 Total assets $ 5,826,666 $ 3,482,843 $ 2,925,757 $ (5,810,764 ) $ 6,424,502 Current liabilities: Current portion of long-term debt $ 34,550 $ — $ 280 $ — $ 34,830 Accounts payable — 70,767 31,532 — 102,299 Accrued salaries and benefits — 69,057 29,990 — 99,047 Other accrued liabilities 36,196 27,676 77,341 — 141,213 Total current liabilities 70,746 167,500 139,143 — 377,389 Long-term debt 3,183,049 — 401,017 (379,008 ) 3,205,058 Deferred tax liabilities – noncurrent — 27,975 54,728 (2,370 ) 80,333 Other liabilities — 103,112 63,322 — 166,434 Total liabilities 3,253,795 298,587 658,210 (381,378 ) 3,829,214 Redeemable noncontrolling interests — — 22,417 — 22,417 Total equity 2,572,871 3,184,256 2,245,130 (5,429,386 ) 2,572,871 Total liabilities and equity $ 5,826,666 $ 3,482,843 $ 2,925,757 $ (5,810,764 ) $ 6,424,502 Acadia Healthcare Company, Inc. Condensed Consolidating Balance Sheets December 31, 2016 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Current assets: Cash and cash equivalents $ — $ 15,681 $ 41,382 $ — $ 57,063 Accounts receivable, net — 209,124 54,203 — 263,327 Other current assets — 61,724 45,813 — 107,537 Total current assets — 286,529 141,398 — 427,927 Property and equipment, net — 940,880 1,762,815 — 2,703,695 Goodwill — 1,935,260 745,928 — 2,681,188 Intangible assets, net — 56,676 26,634 — 83,310 Deferred tax assets – noncurrent 13,522 — 4,606 (14,348 ) 3,780 Derivative instruments 73,509 — — — 73,509 Investment in subsidiaries 4,885,865 — — (4,885,865 ) — Other assets 493,294 40,480 7,189 (489,646 ) 51,317 Total assets $ 5,466,190 $ 3,259,825 $ 2,688,570 $ (5,389,859 ) $ 6,024,726 Current liabilities: Current portion of long-term debt $ 34,550 $ — $ 255 $ — $ 34,805 Accounts payable — 49,205 30,829 — 80,034 Accrued salaries and benefits — 72,835 32,233 — 105,068 Other accrued liabilities 33,616 24,375 64,967 — 122,958 Total current liabilities 68,166 146,415 128,284 — 342,865 Long-term debt 3,230,300 — 512,350 (489,646 ) 3,253,004 Deferred tax liabilities – noncurrent — 40,574 52,294 (14,348 ) 78,520 Other liabilities — 101,938 62,921 — 164,859 Total liabilities 3,298,466 288,927 755,849 (503,994 ) 3,839,248 Redeemable noncontrolling interests — — 17,754 — 17,754 Total equity 2,167,724 2,970,898 1,914,967 (4,885,865 ) 2,167,724 Total liabilities and equity $ 5,466,190 $ 3,259,825 $ 2,688,570 $ (5,389,859 ) $ 6,024,726
Summary of Condensed Consolidating Statement of Comprehensive Income	Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Comprehensive Income Year Ended December 31, 2017 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Revenue before provision for doubtful accounts $ — $ 1,746,656 $ 1,130,578 $ — $ 2,877,234 Provision for doubtful accounts — (35,636 ) (5,282 ) — (40,918 ) Revenue — 1,711,020 1,125,296 — 2,836,316 Salaries, wages and benefits 23,467 902,180 610,513 — 1,536,160 Professional fees — 93,991 102,232 — 196,223 Supplies — 75,248 39,191 — 114,439 Rents and leases — 33,365 43,410 — 76,775 Other operating expenses — 217,900 113,927 — 331,827 Depreciation and amortization — 66,482 76,528 — 143,010 Interest expense, net 61,872 81,274 32,861 — 176,007 Debt extinguishment costs 810 — — — 810 Transaction-related expenses — 11,236 13,031 — 24,267 Total expenses 86,149 1,481,676 1,031,693 — 2,599,518 (Loss) income from continuing operations before income taxes (86,149 ) 229,344 93,603 — 236,798 Equity in earnings of subsidiaries 259,282 — — (259,282 ) — (Benefit from) provision for income taxes (26,456 ) 69,882 (6,217 ) — 37,209 Income (loss) from continuing operations 199,589 159,462 99,820 (259,282 ) 199,589 Income from discontinued operations, net of income taxes — — — — — Net income (loss) 199,589 159,462 99,820 (259,282 ) 199,589 Net loss attributable to noncontrolling interests — — 246 — 246 Net income attributable to Acadia Healthcare Company, Inc. $ 199,589 $ 159,462 $ 100,066 $ (259,282 ) $ 199,835 Other comprehensive income: Foreign currency translation gain — — 207,341 — 207,341 Loss on derivative instruments (33,431 ) — — — (33,431 ) Pension liability adjustment, net — — 1,542 — 1,542 Other comprehensive income (33,431 ) — 208,883 — 175,452 Comprehensive income (loss) $ 166,158 $ 159,462 $ 308,949 $ (259,282 ) $ 375,287 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Comprehensive Income Year Ended December 31, 2016 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Revenue before provision for doubtful accounts $ — $ 1,662,734 $ 1,190,089 $ — $ 2,852,823 Provision for doubtful accounts — (38,349 ) (3,560 ) — (41,909 ) Revenue — 1,624,385 1,186,529 — 2,810,914 Salaries, wages and benefits 28,345 865,104 648,405 — 1,541,854 Professional fees — 89,062 96,424 — 185,486 Supplies — 76,246 41,179 — 117,425 Rents and leases — 34,540 38,808 — 73,348 Other operating expenses — 206,308 106,248 — 312,556 Depreciation and amortization — 58,018 77,085 — 135,103 Interest expense, net 50,921 75,848 54,556 — 181,325 Debt extinguishment costs 4,253 — — — 4,253 Loss on divestiture — 778 178,031 — 178,809 Gain on foreign currency derivatives (523 ) — — — (523 ) Transaction-related expenses — 32,173 16,150 — 48,323 Total expenses 82,996 1,438,077 1,256,886 — 2,777,959 (Loss) income from continuing operations before income taxes (82,996 ) 186,308 (70,357 ) — 32,955 Equity in earnings of subsidiaries 65,560 — — (65,560 ) — (Benefit from) provision for income taxes (21,612 ) 68,335 (17,944 ) — 28,779 Income (loss) from continuing operations 4,176 117,973 (52,413 ) (65,560 ) 4,176 Income from discontinued operations, net of income taxes — — — — — Net income (loss) 4,176 117,973 (52,413 ) (65,560 ) 4,176 Net loss attributable to noncontrolling interests — — 1,967 — 1,967 Net income attributable to Acadia Healthcare Company, Inc. $ 4,176 $ 117,973 $ (50,446 ) $ (65,560 ) $ 6,143 Other comprehensive income: Foreign currency translation loss — — (477,772 ) — (477,772 ) Gain on derivative instruments 40,598 — — — 40,598 Pension liability adjustment, net — — (7,749 ) — (7,749 ) Other comprehensive income 40,598 — (485,521 ) — (444,923 ) Comprehensive income (loss) $ 44,774 $ 117,973 $ (535,967 ) $ (65,560 ) $ (438,780 ) Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Comprehensive Income Year Ended December 31, 2015 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Revenue before provision for doubtful accounts $ — $ 1,415,016 $ 414,603 $ — $ 1,829,619 Provision for doubtful accounts — (32,614 ) (2,513 ) — (35,127 ) Revenue — 1,382,402 412,090 — 1,794,492 Salaries, wages and benefits 20,472 726,215 227,045 — 973,732 Professional fees — 83,422 33,041 — 116,463 Supplies — 65,077 15,586 — 80,663 Rents and leases — 29,094 3,434 — 32,528 Other operating expenses — 170,018 36,728 — 206,746 Depreciation and amortization — 41,768 21,782 — 63,550 Interest expense, net 68,533 17,476 20,733 — 106,742 Debt extinguishment costs 10,818 — — — 10,818 Loss on foreign currency derivatives 1,926 — — — 1,926 Transaction-related expenses — 24,914 11,657 — 36,571 Total expenses 101,749 1,157,984 370,006 — 1,629,739 (Loss) income from continuing operations before income taxes (101,749 ) 224,418 42,084 — 164,753 Equity in earnings of subsidiaries 176,178 — — (176,178 ) — (Benefit from) provision for income taxes (37,047 ) 85,765 4,670 — 53,388 Income (loss) from continuing operations 111,476 138,653 37,414 (176,178 ) 111,365 Income from discontinued operations, net of income taxes — 111 — — 111 Net income (loss) 111,476 138,764 37,414 (176,178 ) 111,476 Net loss attributable to noncontrolling interests — — 1,078 — 1,078 Net income attributable to Acadia Healthcare Company, Inc. $ 111,476 $ 138,764 $ 38,492 $ (176,178 ) $ 112,554 Other comprehensive income: Foreign currency translation loss — — (40,103 ) — (40,103 ) Pension liability adjustment, net — — 3,826 — 3,826 Other comprehensive income — — (36,277 ) — (36,277 ) Comprehensive income (loss) $ 111,476 $ 138,764 $ 2,215 $ (176,178 ) $ 76,277
Summary of Condensed Consolidating Statement of Cash Flows	Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Cash Flows Year Ended December 31, 2017 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Operating activities: Net income (loss) $ 199,589 $ 159,462 $ 99,820 $ (259,282 ) $ 199,589 Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities: Equity in earnings of subsidiaries (259,282 ) — — 259,282 — Depreciation and amortization — 66,482 76,528 — 143,010 Amortization of debt issuance costs 10,270 — (415 ) — 9,855 Equity-based compensation expense 23,467 — — — 23,467 Deferred income tax expense 1,236 28,882 1,254 — 31,372 Debt extinguishment costs 810 — — — 810 Other 4,189 2,498 4,725 — 11,412 Change in operating assets and liabilities, net of effect of acquisitions: Accounts receivable, net — (21,791 ) (6,779 ) — (28,570 ) Other current assets — (6,429 ) 27,237 — 20,808 Other assets 24,549 (3,277 ) 101 (24,549 ) (3,176 ) Accounts payable and other accrued liabilities — 4,909 (15,022 ) — (10,113 ) Accrued salaries and benefits — (3,974 ) (5,014 ) — (8,988 ) Other liabilities — 8,794 3,000 — 11,794 Net cash provided by (used in) continuing operating activities 4,828 235,556 185,435 (24,549 ) 401,270 Net cash used in discontinued operating activities — (1,693 ) — — (1,693 ) Net cash provided by (used in) operating activities 4,828 233,863 185,435 (24,549 ) 399,577 Investing activities: Cash paid for acquisitions, net of cash acquired — — (18,191 ) — (18,191 ) Cash paid for capital expenditures — (161,312 ) (112,865 ) — (274,177 ) Cash paid for real estate acquisitions — (37,047 ) (4,010 ) — (41,057 ) Other — (7,944 ) 4,843 — (3,101 ) Net cash used in investing activities — (206,303 ) (130,223 ) — (336,526 ) Financing activities: Principal payments on long-term debt (34,550 ) (14,250 ) (10,554 ) 24,549 (34,805 ) Repayment of long-term debt (22,500 ) — — — (22,500 ) Common stock withheld for minimum statutory taxes, net (3,455 ) — — — (3,455 ) Other (539 ) 1,225 — — 686 Cash provided by (used in) intercompany activity 56,216 16,644 (72,860 ) — — Net cash (used in) provided by financing activities (4,828 ) 3,619 (83,414 ) 24,549 (60,074 ) Effect of exchange rate changes on cash — — 7,250 — 7,250 Net increase in cash and cash equivalents — 31,179 (20,952 ) — 10,227 Cash and cash equivalents at beginning of the period — 15,681 41,382 — 57,063 Cash and cash equivalents at end of the period $ — $ 46,860 $ 20,430 $ — $ 67,290 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Cash Flows Year Ended December 31, 2016 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Operating activities: Net income (loss) $ 4,176 $ 117,973 $ (52,413 ) $ (65,560 ) $ 4,176 Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities: Equity in earnings of subsidiaries (65,560 ) — — 65,560 — Depreciation and amortization — 58,018 77,085 — 135,103 Amortization of debt issuance costs 10,751 — (427 ) — 10,324 Equity-based compensation expense 28,345 — — — 28,345 Deferred income tax (benefit) expense (2,172 ) 50,611 (19,792 ) — 28,647 Loss from discontinued operations, net of taxes — — — — — Debt extinguishment costs 4,253 — — — 4,253 Loss on divestiture — 778 178,031 — 178,809 (Gain) loss on foreign currency derivatives (523 ) — — — (523 ) Other — 4,022 693 — 4,715 Change in operating assets and liabilities, net of effect of acquisitions: Accounts receivable, net — (24,017 ) 8,299 — (15,718 ) Other current assets — (3,138 ) (17,510 ) — (20,648 ) Other assets (3,109 ) (4,048 ) (306 ) 3,109 (4,354 ) Accounts payable and other accrued liabilities — (45,552 ) 68,245 — 22,693 Accrued salaries and benefits — 3,844 (12,416 ) — (8,572 ) Other liabilities — 4,050 434 — 4,484 Net cash (used in) provided by continuing operating activities (23,839 ) 162,541 229,923 3,109 371,734 Net cash used in discontinued operating activities — (10,256 ) — — (10,256 ) Net cash (used in) provided by operating activities (23,839 ) 152,285 229,923 3,109 361,478 Investing activities: Cash paid for acquisitions, net of cash acquired — (103,359 ) (580,096 ) — (683,455 ) Cash paid for capital expenditures — (177,593 ) (129,879 ) — (307,472 ) Cash paid for real estate acquisitions — (28,956 ) (11,801 ) — (40,757 ) Settlement of foreign currency derivatives — 523 — — 523 Cash received for divestiture 370,000 7,859 (4,593 ) — 373,266 Other — (1,573 ) (897 ) — (2,470 ) Net cash used in investing activities 370,000 (303,099 ) (727,266 ) — (660,365 ) Financing activities: Borrowings on long-term debt 1,480,000 — — — 1,480,000 Borrowings on revolving credit facility 179,000 — — — 179,000 Principal payments on revolving credit facility (337,000 ) — — — (337,000 ) Principal payments on long-term debt (49,706 ) (293,000 ) (3,344 ) 296,109 (49,941 ) Repayment of assumed debt (1,348,389 ) — — — (1,348,389 ) Repayment of long-term debt (200,594 ) — — — (200,594 ) Payment of debt issuance costs (36,649 ) — — — (36,649 ) Issuance of common stock 685,097 — — — 685,097 Common stock withheld for minimum statutory taxes, net (8,846 ) — — — (8,846 ) Other (1,149 ) (2,688 ) — — (3,837 ) Cash (used in) provided by intercompany activity (707,925 ) 460,196 546,947 (299,218 ) — Net cash provided by (used in) financing activities (346,161 ) 164,508 543,603 (3,109 ) 358,841 Effect of exchange rate changes on cash — — (14,106 ) — (14,106 ) Net increase in cash and cash equivalents — 13,694 32,154 — 45,848 Cash and cash equivalents at beginning of the period — 1,987 9,228 — 11,215 Cash and cash equivalents at end of the period $ — $ 15,681 $ 41,382 $ — $ 57,063 Acadia Healthcare Company, Inc. Condensed Consolidating Statement of Cash Flows Year Ended December 31, 2015 (In thousands) Parent Combined Subsidiary Guarantors Combined Non- Guarantors Consolidating Adjustments Total Consolidated Amounts Operating activities: Net income (loss) $ 111,476 $ 138,764 $ 37,414 $ (176,178 ) $ 111,476 Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities: Equity in earnings of subsidiaries (176,178 ) — — 176,178 — Depreciation and amortization — 41,768 21,782 — 63,550 Amortization of debt issuance costs 7,147 — (438 ) — 6,709 Equity-based compensation expense 20,472 — — — 20,472 Deferred income tax (benefit) expense 617 42,246 750 — 43,613 Loss from discontinued operations, net of taxes — (111 ) — — (111 ) Debt extinguishment costs 10,818 — — — 10,818 Loss (gain) on foreign currency derivatives 1,926 — — — 1,926 Other — 1,582 33 — 1,615 Change in operating assets and liabilities, net of effect of acquisitions: Accounts receivable, net — (18,632 ) (6,322 ) — (24,954 ) Other current assets — (1,152 ) (1,565 ) — (2,717 ) Other assets (1,100 ) (8,567 ) 546 1,100 (8,021 ) Accounts payable and other accrued liabilities — (7,583 ) 14,451 — 6,868 Accrued salaries and benefits — 312 1,346 — 1,658 Other liabilities — 9,350 (114 ) — 9,236 Net cash (used in) provided by continuing operating activities (24,822 ) 197,977 67,883 1,100 242,138 Net cash provided by discontinued operating activities — (1,735 ) — — (1,735 ) Net cash (used in) provided by operating activities (24,822 ) 196,242 67,883 1,100 240,403 Investing activities: Cash paid for acquisitions, net of cash acquired — (254,848 ) (319,929 ) — (574,777 ) Cash paid for capital expenditures — (172,329 ) (103,718 ) — (276,047 ) Cash paid for real estate acquisitions — (25,293 ) (1,329 ) — (26,622 ) Settlement of foreign currency derivatives — (1,926 ) — — (1,926 ) Other — (5,099 ) — — (5,099 ) Net cash used in investing activities — (459,495 ) (424,976 ) — (884,471 ) Financing activities: Borrowings on long-term debt 1,150,000 — — — 1,150,000 Borrowings on revolving credit facility 468,000 — — — 468,000 Principal payments on revolving credit facility (310,000 ) — — — (310,000 ) Principal payments on long-term debt (31,965 ) — (1,315 ) 1,315 (31,965 ) Repayment of assumed debt (904,467 ) — — — (904,467 ) Repayment of long-term debt (97,500 ) — — — (97,500 ) Payment of debt issuance costs (26,421 ) — — — (26,421 ) Payment of premium on senior notes (7,480 ) — — — (7,480 ) Issuance of common stock, net 331,308 — — — 331,308 Common stock withheld for minimum statutory taxes, net (7,762 ) — — — (7,762 ) Excess tax benefit from equity awards 309 — — — 309 Other — (420 ) — — (420 ) Cash (used in) provided by intercompany activity (539,200 ) 191,334 350,281 (2,415 ) — Net cash provided by (used in) financing activities 24,822 190,914 348,966 (1,100 ) 563,602 Effect of exchange rate changes on cash — (2,359 ) — — (2,359 ) Net (decrease) increase in cash and cash equivalents — (74,698 ) (8,127 ) — (82,825 ) Cash and cash equivalents at beginning of the period — 76,685 17,355 — 94,040 Cash and cash equivalents at end of the period $ — $ 1,987 $ 9,228 $ — $ 11,215

Description of Business and B45

Description of Business and Basis of Presentation - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)BedsStateFacilities	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Accounting Policies [Abstract]
Number of facilities | Facilities	582
Number of beds | Beds	17,800
Number of operating states | State	39
General and administrative expenses | $	$ 76.4	$ 86.8	$ 68.3

Summary of Significant Accoun46

Summary of Significant Accounting Policies - Summary of Percentage of Revenue before Provision for Doubtful Accounts Generated by Each Payor Type (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	100.00%	100.00%	100.00%
Commercial [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	19.80%	18.70%	23.10%
Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	9.80%	9.40%	11.70%
Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	27.70%	25.40%	33.30%
U.K Public Funded Sources [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	32.60%	35.80%	19.50%
Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	8.70%	9.40%	9.60%
Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	1.40%	1.30%	2.80%

Summary of Significant Accoun47

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017USD ($)Segment	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Significant Accounting Policies [Line Items]
Percentage of revenue		100.00%	100.00%	100.00%
Cost report receivables		$ 9,000,000	$ 7,400,000
Net adjustments to estimated cost report settlements resulted in increases to revenue		200,000	700,000	$ 1,900,000
Costs of providing charity care services		6,600,000	7,100,000	4,600,000
Maximum professional liability risks reinsured in excess of retention level		75,000,000
Professional and general liability reserve		55,000,000	52,300,000
Professional and general liability reserve current		22,800,000	11,700,000
Professional and general liability reserve noncurrent		32,200,000	40,600,000
Insurance receivable		22,700,000	25,900,000
Insurance receivable - current portion		17,588,000	6,472,000
Insurance receivable noncurrent		5,100,000	19,400,000
Workers compensation insurance claims deductible per accident		500,000
Reserve for workers compensation liability		18,500,000	16,600,000
Accrued salaries and benefits		10,000,000	10,000,000
Other long-term liabilities		8,500,000	6,600,000
Depreciation expense		$ 143,000,000	134,800,000	63,000,000
Number of operating segment | Segment		2
Number of reporting unit | Segment		2
Intangible assets impairment charges		$ 0	$ 0	$ 0
U.S. federal corporate tax rate		35.00%	35.00%	35.00%
Scenario, Forecast [Member]
Significant Accounting Policies [Line Items]
U.S. federal corporate tax rate	21.00%
Medicare and Medicaid [Member]
Significant Accounting Policies [Line Items]
Percentage of revenue		38.00%	35.00%	45.00%
Maximum [Member]
Significant Accounting Policies [Line Items]
Maximum professional liability aggregate policy limit		$ 78,000,000
Maximum [Member] | Building and Improvements [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life		50 years
Maximum [Member] | Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life		7 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Maximum professional liability aggregate retention level		$ 3,000,000
Minimum [Member] | Building and Improvements [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life		10 years
Minimum [Member] | Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life		3 years
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | United Kingdom [Member]
Significant Accounting Policies [Line Items]
Percentage of revenue generated by facility		36.00%	38.00%	20.00%

Summary of Significant Accoun48

Summary of Significant Accounting Policies - Summary of Activity in Company's Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Balance at Beginning of Period	$ 38,916	$ 29,332	$ 22,449
Additions Charged to Costs and Expenses	40,918	41,909	35,127
Accounts Written Off, Net of Recoveries	(40,031)	(32,325)	(28,244)
Balance at End of Period	$ 39,803	$ 38,916	$ 29,332

Summary of Significant Accoun49

Summary of Significant Accounting Policies - Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other receivables	$ 30,455	$ 44,975
Prepaid expenses	27,320	27,455
Insurance receivable - current portion	17,588	6,472
Income taxes receivable	15,056	11,714
Workers' compensation deposits - current portion	10,000	10,000
Inventory	4,787	4,633
Other	2,129	2,288
Other current assets	$ 107,335	$ 107,537

Summary of Significant Accoun50

Summary of Significant Accounting Policies - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accrued expenses	$ 37,268	$ 37,323
Accrued interest	36,370	33,616
Unearned income	31,342	28,805
Insurance liability - current portion	22,788	11,672
Accrued property taxes	3,945	2,732
Income taxes payable	1,012	527
Other	8,488	8,283
Other accrued liabilities	$ 141,213	$ 122,958

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations									$ 199,835	$ 6,143	$ 112,443
Income from discontinued operations											111
Net income attributable to Acadia Healthcare Company, Inc.	$ 69,629	$ 45,618	$ 49,630	$ 34,958	$ 41,818	$ (117,808)	$ 56,445	$ 25,688	$ 199,835	$ 6,143	$ 112,554
Denominator:
Weighted average shares outstanding for basic earnings per share									86,948	85,701	68,085
Effects of dilutive instruments									112	271	306
Shares used in computing diluted earnings per common share									87,060	85,972	68,391
Basic earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations									$ 2.30	$ 0.07	$ 1.65
Income from discontinued operations									0	0	0
Net income attributable to Acadia Healthcare Company, Inc.:	$ 0.80	$ 0.52	$ 0.57	$ 0.40	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	2.30	0.07	1.65
Diluted earnings per share attributable to Acadia Healthcare Company, Inc.:
Income from continuing operations									2.30	0.07	1.64
Income from discontinued operations									0	0	0
Net income attributable to Acadia Healthcare Company, Inc.:	$ 0.80	$ 0.52	$ 0.57	$ 0.40	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	$ 2.30	$ 0.07	$ 1.64

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	1.4	1.1	0.8

Acquisitions - 2017 Acquisition

Acquisitions - 2017 Acquisitions - Additional Information (Detail) - Aspire [Member] $ in Millions	Nov. 13, 2017USD ($)Beds
Business Acquisition [Line Items]
Number of beds | Beds	36
Business acquisition cash consideration | $	$ 21.3

Acquisitions - 2016 US Acquisit

Acquisitions - 2016 US Acquisitions - Additional Information (Detail) $ in Millions	Jun. 01, 2016USD ($)Beds	May 01, 2016USD ($)Beds	Apr. 01, 2016USD ($)Beds
Pocono Mountain Recovery Center [Member]
Business Acquisition [Line Items]
Number of beds | Beds	108
Business acquisition cash consideration | $	$ 25.4
Serenity Knolls Inc [Member]
Business Acquisition [Line Items]
Number of beds | Beds			30
Business acquisition cash paid | $			$ 10
Tennessee [Member] | TrustPoint Hospital [Member]
Business Acquisition [Line Items]
Number of beds | Beds		100
Business acquisition cash paid | $		$ 62.7

Acquisitions - Priory Acquisiti

Acquisitions - Priory Acquisition - Additional Information (Detail) $ in Thousands, £ in Millions	Nov. 30, 2016USD ($)	Nov. 30, 2016GBP (£)	Oct. 18, 2016BedFacility	Feb. 16, 2016USD ($)BedFacilityshares	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Business Acquisition [Line Items]
Number of beds to be sold | Bed			1,000
Cash received from sale of business		£ 320												$ 373,266
Loss on divestiture														(178,809)
Revenue													$ 2,836,316	2,810,914	$ 1,794,492
Income from continuing operations before income taxes					$ 60,639	$ 61,459	$ 66,216	$ 48,484	$ 42,438	$ (115,814)	$ 73,852	$ 32,479	$ 236,798	32,955	164,753
U.K. Behavioral Health Facilities [Member]
Business Acquisition [Line Items]
Number of facilities to be sold | Facility			21
De novo Behavioral Health Facility [Member]
Business Acquisition [Line Items]
Number of facilities to be sold | Facility			1
U.K. Disposal Group [Member]
Business Acquisition [Line Items]
Loss on divestiture	$ 175,000									$ 174,700				175,000
Revenue														154,700	58,500
Income from continuing operations before income taxes														81,200	$ 17,000
U.K. Disposal Group [Member] | Allocation of Goodwill [Member]
Business Acquisition [Line Items]
Loss on divestiture														106,900
U.K. Disposal Group [Member] | Estimated Transaction Related Expense [Member]
Business Acquisition [Line Items]
Loss on divestiture														26,100
U.K. Disposal Group [Member] | Loss on Sale of Properties [Member]
Business Acquisition [Line Items]
Loss on divestiture														$ 42,000
Priory [Member]
Business Acquisition [Line Items]
Total consideration related to acquisition				$ 2,200,000
Business acquisition cash paid				$ 1,900,000
Shares issued for acquisition | shares				4,033,561
Number of facilities acquired | Facility				324
Number of beds | Bed				7,100

Acquisitions - Summary of Acqui

Acquisitions - Summary of Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill associated with domestic acquisitions	$ 2,751,174	$ 2,681,188
Domestic Acquisitions in 2016 [Member]
Business Acquisition [Line Items]
Goodwill associated with domestic acquisitions	$ 31,400

Acquisitions - Summary of Acq57

Acquisitions - Summary of Acquisitions (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 2,751,174	$ 2,681,188
2016 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		12,741
Accounts receivable		62,096
Prepaid expenses and other current assets		8,024
Property and equipment		1,633,556
Goodwill		775,317
Intangible assets		23,538
Other assets		8,909
Total assets acquired		2,524,181
Accounts payable		24,952
Accrued salaries and benefits		40,506
Other accrued expenses		48,696
Deferred tax liabilities - noncurrent		56,731
Debt		1,348,389
Other liabilities		91,554
Total liabilities assumed		1,610,828
Net assets acquired		913,353
Other [Member] | 2016 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		2,488
Accounts receivable		4,264
Prepaid expenses and other current assets		103
Property and equipment		35,400
Goodwill		96,052
Intangible assets		338
Other assets		47
Total assets acquired		138,692
Accounts payable		749
Accrued salaries and benefits		918
Other accrued expenses		391
Deferred tax liabilities - noncurrent		269
Other liabilities		30,243
Total liabilities assumed		32,570
Net assets acquired		106,122
Priory [Member] | 2016 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		10,253
Accounts receivable		57,832
Prepaid expenses and other current assets		7,921
Property and equipment		1,598,156
Goodwill		679,265
Intangible assets		23,200
Other assets		8,862
Total assets acquired		2,385,489
Accounts payable		24,203
Accrued salaries and benefits		39,588
Other accrued expenses		48,305
Deferred tax liabilities - noncurrent		56,462
Debt		1,348,389
Other liabilities		61,311
Total liabilities assumed		1,578,258
Net assets acquired		$ 807,231

Acquisitions - Transaction Rela

Acquisitions - Transaction Related Expenses as Incurred (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Combinations [Abstract]
Severance and contract termination costs	$ 14,709	$ 12,415	$ 8,466
Legal, accounting and other fees	9,558	21,058	17,768
Advisory and financing commitment fees		14,850	10,337
Transaction-related expenses	$ 24,267	$ 48,323	$ 36,571

Other Intangible Assets - Other

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 3,247	$ 3,247
Intangible assets not subject to amortization, Gross Carrying Amount	87,348	83,310
Total	90,595	86,557
Intangible assets subject to amortization, Accumulated Amortization	(3,247)	(3,247)
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Total	(3,247)	(3,247)
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	2,100	2,100
Intangible assets subject to amortization, Accumulated Amortization	(2,100)	(2,100)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,147	1,147
Intangible assets subject to amortization, Accumulated Amortization	(1,147)	(1,147)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	12,266	12,228
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	60,586	57,538
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	14,496	13,544
Intangible assets not subject to amortization, Accumulated Amortization	$ 0	$ 0

Other Intangible Assets - Addit

Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 0.4	$ 0.5

Long-Term Debt - Components of

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Sep. 21, 2015
Debt Instrument [Line Items]
Less: unamortized debt issuance costs, discount and premium	$ (50,432)	$ (59,816)
Long-term debt	3,239,888	3,287,809
Long-term debt	3,239,888	3,287,809
Less: current portion	(34,830)	(34,805)
Long-term debt	3,205,058	3,253,004
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes	150,000	150,000
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes	300,000	300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	650,000	650,000	$ 650,000
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Senior Notes	390,000	390,000
Amended and Restated Senior Credit Facility [Member] | Senior Secured Term A Loans [Member]
Debt Instrument [Line Items]
Senior Secured	380,000	400,000
Amended and Restated Senior Credit Facility [Member] | Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	1,398,400	1,435,450
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 21,920	$ 22,175

Long-Term Debt - Components o62

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
Senior notes maturity year	2,021	2,021
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
Senior notes maturity year	2,022	2,022
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
Senior notes maturity year	2,023	2,023
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%
Senior notes maturity year	2,024	2,024
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%	9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%	9.50%

Long-Term Debt (Amended and Res

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - USD ($)

Dec. 29, 2017

May 10, 2017

May 09, 2017

Nov. 30, 2016

Sep. 21, 2016

Sep. 20, 2016

May 26, 2016

May 25, 2016

Feb. 16, 2016

Dec. 15, 2015

Dec. 31, 2012

Apr. 01, 2011

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Nov. 22, 2016

Dec. 15, 2014

Debt Instrument [Line Items]

Debt extinguishment costs

$ (810,000)

$ (4,253,000)

$ (10,818,000)

Line of Credit Facility, Expiration Date

Feb. 13, 2019

Term loan repayments

$ 22,500,000

Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA

$ 40,000,000

Tranche B-1 Repricing Amendment [Member]

Debt Instrument [Line Items]

Term loan repayments

7,700,000

Tranche B-2 Repricing Amendment [Member]

Debt Instrument [Line Items]

Debt extinguishment costs

$ 3,400,000

Term loan repayments

$ 14,800,000

Senior Secured Revolving Line of Credit [Member]

Debt Instrument [Line Items]

Line of credit

$ 300,000,000

Term Loan A- Facility [Member]

Debt Instrument [Line Items]

Line of credit

600,600,000

Eurodollar [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.75%

Base Rate Loans [Member]

Debt Instrument [Line Items]

Interest on borrowings

1.75%

Amended and Restated Senior Credit Facility [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Dec. 31, 2012

Apr. 1, 2011

Additional term loans

$ 135,000,000

Debt extinguishment costs

$ 800,000

Line of Credit Facility, Expiration Date

Nov. 30, 2021

Debt Instrument, Interest Rate, Decrease

0.50%

Amount available under revolving line of credit

$ 493,400,000

Debt instrument maturity date

Nov. 30, 2021

Feb. 11, 2022

Term loan repayments

$ 1,300,000

Amended and Restated Senior Credit Facility [Member] | Maximum [Member]

Debt Instrument [Line Items]

Fair market value of real property

$ 5,000,000

Amended and Restated Senior Credit Facility [Member] | Tranche B-1 Repricing Amendment [Member]

Debt Instrument [Line Items]

Date entered into an agreement

May 26, 2016

Amended and Restated Senior Credit Facility [Member] | Tranche B-2 Repricing Amendment [Member]

Debt Instrument [Line Items]

Debt extinguishment costs

$ 3,400,000

Amended and Restated Senior Credit Facility [Member] | Third Repricing Amendment [Member]

Debt Instrument [Line Items]

Debt extinguishment costs

$ 800,000

Amended and Restated Senior Credit Facility [Member] | Ninth Amendment [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Jan. 25, 2016

Restrictive covenants on investments, Description

The Ninth Amendment modified certain definitions and provided increased flexibility to the Company in terms of its financial covenants. The Company’s baskets for permitted investments were also increased to provide increased flexibility for it to invest in non-wholly owned subsidiaries, joint ventures and foreign subsidiaries. The Company may now invest in non-wholly owned subsidiaries and joint ventures up to 10.0% of the Company and its subsidiaries’ total assets in any four consecutive fiscal quarter period, and up to 12.5% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The Company may also invest in foreign subsidiaries that are not loan parties up to 10% of the Company and its subsidiaries’ total assets in any consecutive four fiscal quarter period, and up to 15% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The foregoing permitted investments are subject to an aggregate cap of 25% of the Company and its subsidiaries’ total assets in any fiscal year.

Amended and Restated Senior Credit Facility [Member] | Second Incremental Amendment [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Feb. 16, 2016

New incremental Term Loan B facility

955,000,000

Amended and Restated Senior Credit Facility [Member] | Senior Secured Revolving Line of Credit [Member]

Debt Instrument [Line Items]

Line of credit

$ 500,000,000

$ 300,000,000

Amended and Restated Senior Credit Facility [Member] | TLB Facility Due on February 16, 2023 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,400,000

Amended and Restated Senior Credit Facility [Member] | Term Loan A- Facility [Member]

Debt Instrument [Line Items]

Line of credit

$ 400,000,000

Amended and Restated Senior Credit Facility [Member] | Standby Letters of Credit [Member]

Debt Instrument [Line Items]

New incremental Term Loan B facility

$ 6,600,000

Amended and Restated Senior Credit Facility [Member] | Eurodollar [Member]

Debt Instrument [Line Items]

Basis spread on variable rate

1.00%

Amended and Restated Senior Credit Facility [Member] | Eurodollar [Member] | Tranche B-1 Repricing Amendment [Member]

Debt Instrument [Line Items]

Interest on borrowings

3.00%

3.50%

Amended and Restated Senior Credit Facility [Member] | Eurodollar [Member] | Tranche B-2 Repricing Amendment [Member]

Debt Instrument [Line Items]

Interest on borrowings

3.00%

3.75%

Amended and Restated Senior Credit Facility [Member] | Eurodollar [Member] | Third Repricing Amendment [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.75%

3.00%

Amended and Restated Senior Credit Facility [Member] | Base Rate Loans [Member]

Debt Instrument [Line Items]

Basis spread on variable rate

0.50%

Amended and Restated Senior Credit Facility [Member] | Base Rate Loans [Member] | Tranche B-1 Repricing Amendment [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.00%

2.50%

Amended and Restated Senior Credit Facility [Member] | Base Rate Loans [Member] | Tranche B-2 Repricing Amendment [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.00%

2.75%

Amended and Restated Senior Credit Facility [Member] | Base Rate Loans [Member] | Third Repricing Amendment [Member]

Debt Instrument [Line Items]

Interest on borrowings

1.75%

2.00%

Amended and Restated Senior Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.75%

Amended and Restated Senior Credit Facility [Member] | June 30, 2017 to December 31, 2019 [Member]

Debt Instrument [Line Items]

Term loan principal repayments

$ 5,000,000

Term loan repayments

$ 1,300,000

Amended and Restated Senior Credit Facility [Member] | June 30, 2017 to December 31, 2019 [Member] | TLB Facility Due on February 16, 2023 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,400,000

Amended and Restated Senior Credit Facility [Member] | September 30, 2015 to December 31, 2015 [Member]

Debt Instrument [Line Items]

Term loan repayments

1,300,000

Amended and Restated Senior Credit Facility [Member] | September 30, 2015 to December 31, 2015 [Member] | TLB Facility Due on February 16, 2023 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,400,000

Amended and Restated Senior Credit Facility [Member] | March 31, 2020 to December 31, 2020 [Member]

Debt Instrument [Line Items]

Term loan principal repayments

7,500,000

Term loan repayments

$ 1,300,000

Amended and Restated Senior Credit Facility [Member] | March 31, 2020 to December 31, 2020 [Member] | TLB Facility Due on February 16, 2023 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,400,000

Amended and Restated Senior Credit Facility [Member] | March 31, 2021 to September 30, 2021 [Member]

Debt Instrument [Line Items]

Term loan principal repayments

$ 10,000,000

Long-Term Debt (6.125% Senior N

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($)	Mar. 12, 2013	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Issued Senior Notes	$ 150,000,000
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		Payable semi-annually in arrears on March 15 and September 15 of each year.

Long-Term Debt (5.125% Senior N

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($)	Jul. 01, 2014	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Issued Senior Notes	$ 300,000,000
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 1, 2022
Interest on the notes		Payable semi-annually in arrears on January 1 and July 1 of each year.

Long-Term Debt (5.625% Senior N

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Sep. 21, 2015	Feb. 11, 2015
Debt Instrument [Line Items]
Issued Senior Notes			$ 275,000,000	$ 375,000,000
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Senior Notes	$ 650,000,000	$ 650,000,000	$ 650,000,000
Debt instrument maturity date	Feb. 15, 2023

Long-Term Debt (6.500% Senior N

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)	Feb. 16, 2016	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000
Debt instrument interest rate	6.50%	6.50%	6.50%
Debt instrument maturity date	Mar. 1, 2024
Interest on the notes		Payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

Long-Term Debt (9.0% and 9.5% R

Long-Term Debt (9.0% and 9.5% Revenue Bonds) - Additional Information (Detail) - USD ($) $ in Thousands	Nov. 11, 2012	Dec. 31, 2017	Dec. 31, 2016
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds		$ 21,920	$ 22,175
9.0% and 9.5% Revenue Bonds [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 23,000
Debt service reserve fund within other assets		$ 2,300	$ 2,300
Debt instrument premium	2,600
9.0% and 9.5% Revenue Bonds [Member] | Fair Value [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	25,600
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		9.00%	9.00%
9.0% Revenue Bonds [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 7,500
Debt instrument interest rate	9.00%
Debt instrument maturity date	Dec. 1, 2030
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		9.50%	9.50%
9.5% Revenue Bonds [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 15,500
Debt instrument interest rate	9.50%
Debt instrument maturity date	Dec. 1, 2040

Long-Term Debt (Debt Issuance C

Long-Term Debt (Debt Issuance Costs) - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt issuance costs	$ 46.5	$ 55.3
Accumulated amortization	27.5	18.9
Amortization expenses reported as interest expense	$ 8.6	$ 8.6	$ 5.1

Long-Term Debt (Other) - Summar

Long-Term Debt (Other) - Summary of Aggregate Maturities of Long-Term Debt (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Debt Disclosure [Abstract]
2,018	$ 34,830
2,019	34,855
2,020	44,880
2,021	474,910
2,022	767,240
Thereafter	1,933,605
Total	$ 3,290,320

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Feb. 16, 2016	Jan. 12, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 03, 2016
Equity [Line Items]
Preferred stock, number of shares proposed to be issued			10,000,000	10,000,000
Common stock, number of shares proposed to be issued			180,000,000	180,000,000	90,000,000
Common stock voting rights			One vote for each share
Common stock offered		11,500,000	87,060,114	86,688,199
Common stock offer price		$ 61	$ 0.01	$ 0.01
Underwriting discount amount		$ 15,800
Additional offering-related costs		700
Net proceeds from sale of shares		$ 685,000		$ 685,097	$ 331,308
Priory [Member]
Equity [Line Items]
Total consideration related to acquisition	$ 2,200,000
Business acquisition cash paid	$ 1,900,000
Shares issued for acquisition	4,033,561
Maximum [Member]
Equity [Line Items]
Preferred stock, number of shares proposed to be issued			10,000,000
Maximum [Member] | Amendment [Member]
Equity [Line Items]
Common stock, number of shares proposed to be issued						180,000,000

Equity-Based Compensation - Add

Equity-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	8,200,000	8,200,000
Equity incentive plan available for future grant	4,498,687	4,498,687
Annual increments in employee grants		25.00%
Stock options, contractual term		10 years
Equity-based compensation expense		$ 23,467,000	$ 28,345,000	$ 20,472,000
Unrecognized compensation expense related to unvested options		$ 42,500,000
Vesting period		1 year 2 months 12 days
Vesting targets		$ (5,700,000)
Warrant outstanding	$ 0	0
Deferred income tax benefit	$ 20,200,000	31,372,000	28,647,000	$ 43,613,000
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit		$ 9,200,000	$ 10,700,000

Equity-Based Compensation - Sto

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options outstanding, Beginning balance	1,000,946	694,743
Options granted	259,300	503,850
Options exercised	(87,367)	(57,397)
Options cancelled	(198,313)	(140,250)
Options outstanding, Ending balance	974,566	1,000,946	694,743
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 49.42	$ 42.87
Options exercisable, Ending balance	405,634	288,959
Options granted, Weighted Average Exercise Price	$ 42.25	$ 57.98
Options exercised, Weighted Average Exercise Price	25.92	31.92
Options cancelled, Weighted Average Exercise Price	54.71	57.13
Options outstanding, Weighted Average Exercise Price, Ending balance	$ 47.89	$ 49.42	$ 42.87
Options outstanding, Aggregate Intrinsic Value, Beginning balance	$ 8,166	$ 20,717
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 41.20	$ 42.81
Options granted, Aggregate Intrinsic Value	$ 205	$ 297
Options granted, Weighted Average Remaining Contractual Term	9 years 3 months 19 days	9 years 3 months 11 days
Options exercised, Aggregate Intrinsic Value	$ 1,636	$ 1,530
Options outstanding, Weighted Average Remaining Contractual Term	7 years 5 months 16 days	7 years 9 months 18 days	7 years 8 months 12 days
Options cancelled, Aggregate Intrinsic Value	$ 0	$ 0
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	6 years 7 days	6 years 2 months 19 days
Options outstanding, Aggregate Intrinsic Value, Ending balance	$ 3,802	$ 8,166	$ 20,717
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 3,549	$ 6,111

Equity-Based Compensation - Res

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	844,419	944,562
Granted, Number of Shares	404,224	387,347
Cancelled, Number of Shares	(145,981)	(122,178)
Vested, Number of Shares	(292,794)	(365,312)
Unvested, Number of Shares/Units, Ending balance	809,868	844,419
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 55.76	$ 52.74
Granted, Weighted Average Grant-Date Fair Value	42.38	55.38
Cancelled, Weighted Average Grant-Date Fair Value	55.03	57.02
Vested, Weighted Average Grant-Date Fair Value	53.07	47.18
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 50.19	$ 55.76

Equity-Based Compensation - R75

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	273,599	218,084
Granted, Number of Units	219,840	230,750
Cancelled, Number of Units	0	0
Vested, Number of Units	(132,530)	(175,235)
Unvested, Number of Shares/Units, Ending balance	360,909	273,599
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 59.68	$ 56.97
Granted, Weighted Average Grant-Date Fair Value	43.23	56.95
Cancelled, Weighted Average Grant-Date Fair Value	0	0
Vested, Weighted Average Grant-Date Fair Value	58.67	52.71
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 50.04	$ 59.68

Equity-Based Compensation - Sch

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant-date fair value of options	$ 14.39	$ 18.96
Risk-free interest rate	2.00%	1.40%
Expected volatility	33.00%	33.00%
Expected life (in years)	5 years 6 months	5 years 6 months

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	Nov. 30, 2016	Sep. 30, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Examination [Line Items]
Increase in income tax provision due to adoption of ASU 2016-09				$ 1,700,000
Percentage increase in income tax provision due to adoption of ASU 2016-09				0.70%
Valuation allowance against deferred tax assets				$ 21,155,000	$ 16,031,000
Domestic net operating loss carryforward				0	28,400,000
Foreign net operating loss carryforwards				93,900,000	92,200,000
State net operating loss carry forwards				$ 256,900,000	223,300,000
Operating loss carryforwards expiration start year				2,018
Operating loss carryforwards expiration end year				2,036
Expiration of State tax credits				2,026
State tax credits				$ 900,000
Income taxes receivable				15,056,000	11,714,000
Income tax payable included in other accrued liabilities				1,012,000	527,000
Unrecognized tax benefits				6,104,000	6,949,000	$ 4,511,000	$ 2,923,000
Interest and penalties related to unrecognized tax benefits				$ 100,000	900,000
Loss on divestiture					$ (178,809,000)
U.S. federal statutory rate on income before income taxes				35.00%	35.00%	35.00%
Transition tax on certain repatriated earnings of foreign subsidiaries payable period				8 years
Provisional tax amount				$ 20,200,000
Deferred tax balance				$ 20,200,000
U.K. Disposal Group [Member]
Income Tax Examination [Line Items]
Loss on divestiture	$ 175,000,000	$ 174,700,000			$ 175,000,000
Scenario, Forecast [Member]
Income Tax Examination [Line Items]
U.S. federal statutory rate on income before income taxes			21.00%
Maximum [Member]
Income Tax Examination [Line Items]
Exemption of tax credit				50.00%
Prior Period [Member]
Income Tax Examination [Line Items]
Adjustment for prior period excess tax benefits				$ 8,600,000
Internal Revenue Service (IRS) [Member] | Earliest Tax Year [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service				2,014
Internal Revenue Service (IRS) [Member] | Latest Tax Year [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service				2,016
Payroll [Member] | Maximum [Member]
Income Tax Examination [Line Items]
Exemption of tax credit				15.00%
Foreign Tax Authority [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service minimum				2,013
Period of examination by internal revenue service maximum				2,016
State and Local Jurisdiction [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service minimum				2,011
Period of examination by internal revenue service maximum				2,016
Other Liabilities [Member]
Income Tax Examination [Line Items]
Unrecognized tax benefits				$ 6,400,000	$ 7,800,000
Non US Subsidiaries [Member]
Income Tax Examination [Line Items]
Undistributed earnings of the foreign subsidiaries				$ 0

Income Taxes - Components of Pr

Income Taxes - Components of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal		$ 3,325	$ 572	$ (218)
State		680	(863)	4,078
Foreign		1,832	423	5,915
Total current		5,837	132	9,775
Deferred:
Federal		27,179	45,077	40,635
State		4,408	1,491	5,349
Foreign		(215)	(17,921)	(2,371)
Total deferred provision	$ 20,200	31,372	28,647	43,613
Provision for income taxes		$ 37,209	$ 28,779	$ 53,388

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. federal statutory rate on income before income taxes	35.00%	35.00%	35.00%
Impact of foreign operations	(14.10%)	(13.50%)	(10.00%)
Impact of foreign divestiture		39.20%
Effects of statutory rate change	(8.50%)	(14.50%)
State income taxes, net of federal tax effect	2.10%	7.50%	4.80%
Permanent differences	1.80%	8.30%	4.20%
Transaction related items		25.90%
Change in valuation allowance	1.60%	2.80%	1.20%
Unrecognized tax benefit release	(0.80%)	(7.20%)
Other	(1.40%)	3.80%	(2.80%)
Effective income tax rate	15.70%	87.30%	32.40%

Income Taxes - Summary of Domes

Income Taxes - Summary of Domestic and Foreign Components of Income (Loss) from Continuing Operations before Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Income (loss) from continuing operations before income taxes	$ 60,639	$ 61,459	$ 66,216	$ 48,484	$ 42,438	$ (115,814)	$ 73,852	$ 32,479	$ 236,798	$ 32,955	$ 164,753
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Income (loss) from continuing operations before income taxes									120,905	(144,717)	28,316
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Income (loss) from continuing operations before income taxes									$ 115,893	$ 177,672	$ 136,437

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating losses and tax credit carryforwards - federal and state	$ 29,409	$ 37,638
Bad debt allowance	827	15,381
Accrued compensation and severance	14,179	23,379
Pension reserves	1,494	697
Insurance reserves	13,483	17,468
Leases	5,332	2,926
Accrued expenses	3,114
Interest carryforwards	5,074
Other assets	1,747	2,038
Total gross deferred tax assets	74,659	99,527
Less: valuation allowance	(21,155)	(16,031)
Deferred tax assets	53,504	83,496
Deferred tax liabilities:
Fixed asset basis difference	(54,214)	(45,510)
Prepaid items	(1,490)	(1,324)
Intangible assets	(70,820)	(77,655)
Accrued expenses		(4,531)
Other liabilities	(3,582)	(29,216)
Total deferred tax liabilities	(130,106)	(158,236)
Total net deferred tax liability	$ (76,602)	$ (74,740)

Income Taxes - Unrecognized Inc

Income Taxes - Unrecognized Income Tax Benefits Net of Federal Benefit (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Balance at January 1	$ 6,949	$ 4,511	$ 2,923
Additions based on tax positions related to the current year	5,488		1,516
Additions for tax positions of prior years	95	5,427	2,874
Reductions as a result of the lapse of applicable statutes of limitations	(6,428)	(2,989)	(2,802)
Balance at December 31	$ 6,104	$ 6,949	$ 4,511

Derivatives - Additional Inform

Derivatives - Additional Information (Detail)	1 Months Ended		12 Months Ended
	May 31, 2016USD ($)	May 31, 2016GBP (£)	Dec. 31, 2016USD ($)	Dec. 31, 2017USD ($)	May 31, 2016GBP (£)	Sep. 21, 2015USD ($)	Feb. 11, 2015USD ($)	Jul. 01, 2014USD ($)	Mar. 12, 2013USD ($)
Derivative [Line Items]
Cross currency swap assets			$ 73,500,000	$ 13,000,000
Prior Period [Member]
Derivative [Line Items]
Gains associated with foreign currency forward contracts			$ 500,000
6.125% Senior Notes Due 2021 [Member]
Derivative [Line Items]
Principal amount									$ 150,000,000
Debt instrument interest rate			6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Derivative [Line Items]
Principal amount								$ 300,000,000
Debt instrument interest rate			5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Derivative [Line Items]
Principal amount						$ 275,000,000	$ 375,000,000
Debt instrument interest rate			5.625%	5.625%		5.625%	5.625%
Cross Currency Swap Assets [Member]
Derivative [Line Items]
Notional amount	$ 650,000,000				£ 449,300,000
Cross currency swap agreement cash flow due to interest payment	$ 35,800,000	£ 24,700,000
Derivative exchange rate	1.45				1.45
Cross Currency Swap Assets [Member] | 6.125% Senior Notes Due 2021 [Member]
Derivative [Line Items]
Principal amount	$ 150,000,000
Debt instrument interest rate	6.125%				6.125%
Cross Currency Swap Assets [Member] | 5.125% Senior Notes Due 2022 [Member]
Derivative [Line Items]
Principal amount	$ 300,000,000
Debt instrument interest rate	5.125%				5.125%
Cross Currency Swap Assets [Member] | 5.625% Senior Notes Due 2023 [Member]
Derivative [Line Items]
Principal amount	$ 200,000,000
Debt instrument interest rate	5.625%				5.625%

Fair Value Measurements - Carry

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative instruments	$ 12,997	$ 73,509
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative instruments	12,997	73,509
Contingent consideration liabilities		107
Fair Value [Member] | Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,749,185	1,799,993
Fair Value [Member] | 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	150,134	152,186
Fair Value [Member] | 5.125% Senior Notes Due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	296,914	293,595
Fair Value [Member] | 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	651,519	640,574
Fair Value [Member] | 6.500% Senior Notes due 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	397,541	389,847
Fair Value [Member] | 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	22,289	22,959
Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative instruments	12,997	73,509
Contingent consideration liabilities		107
Carrying Amount [Member] | Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,749,185	1,799,993
Carrying Amount [Member] | 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	148,098	147,574
Carrying Amount [Member] | 5.125% Senior Notes Due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	296,174	295,442
Carrying Amount [Member] | 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	641,891	640,574
Carrying Amount [Member] | 6.500% Senior Notes due 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	382,251	381,268
Carrying Amount [Member] | 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	$ 22,289	$ 22,959

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2017	Dec. 31, 2016	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%	9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%	9.50%

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Leased Assets [Line Items]
Rent expense	$ 76,775	$ 73,348	$ 32,528
Minimum [Member]
Operating Leased Assets [Line Items]
Original terms of the leases	5 years
Maximum [Member]
Operating Leased Assets [Line Items]
Original terms of the leases	30 years

Leases - Schedule of Aggregate

Leases - Schedule of Aggregate Minimum Lease Payments under Non-cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Leases [Abstract]
2,018	$ 69,613
2,019	64,556
2,020	60,156
2,021	56,620
2,022	51,071
Thereafter	835,369
Total minimum rental obligations	$ 1,137,385

Noncontrolling Interests - Addi

Noncontrolling Interests - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017Facilities
Noncontrolling Interest [Line Items]
Number of facilities operated by non-wholly owned subsidiaries	3
Minimum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	60.00%
Maximum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	75.00%

Noncontrolling Interests - Summ

Noncontrolling Interests - Summary of Redeemable Noncontrolling Interests (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Noncontrolling Interest [Abstract]
Beginning Balance	$ 17,754	$ 8,055
Acquisition of redeemable noncontrolling interests	4,909	11,666
Net loss attributable to noncontrolling interests	(246)	(1,967)
Ending Balance	$ 22,417	$ 17,754

Segment Information - Additiona

Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017BedsStateFacilities
Segment Reporting Information [Line Items]
Number of facilities | Facilities	582
Number of beds | Beds	17,800
Number of operating states | State	39
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities | Facilities	209
Number of beds | Beds	8,900
Number of operating states | State	39
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities | Facilities	373
Number of beds | Beds	8,900

Segment Information - Summary o

Segment Information - Summary of Reconciliation of Segment EBITDA to Income from Continuing Operations (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Revenue									$ 2,836,316	$ 2,810,914	$ 1,794,492
Segment EBITDA									604,359	608,590	404,832
Equity-based compensation expense									(23,467)	(28,345)	(20,472)
Debt extinguishment costs									(810)	(4,253)	(10,818)
Loss on divestiture										(178,809)
Gain on foreign currency derivatives										523	(1,926)
Transaction-related expenses									(24,267)	(48,323)	(36,571)
Interest expense, net									(176,007)	(181,325)	(106,742)
Depreciation and amortization									(143,010)	(135,103)	(63,550)
Income from continuing operations before income taxes	$ 60,639	$ 61,459	$ 66,216	$ 48,484	$ 42,438	$ (115,814)	$ 73,852	$ 32,479	236,798	32,955	164,753
U.S. Facilities [Member] | Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue									1,809,844	1,698,525	1,426,205
Segment EBITDA									475,260	443,341	377,587
U.K. Facilities [Member] | Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue									1,026,472	1,110,361	360,698
Segment EBITDA									198,566	245,046	90,035
Corporate and Other [Member] | Corporate Reconciling Items and Eliminations [Member]
Segment Reporting Information [Line Items]
Revenue										2,028	7,589
Segment EBITDA									$ (69,467)	$ (79,797)	$ (62,790)

Segment Information - Summary92

Segment Information - Summary of Financial Information by Operating Segment, Goodwill (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Goodwill:
Beginning balance	$ 2,681,188
Increase from 2017 acquisition	15,302
Foreign currency translation	60,770
Purchase price allocation and other	(6,086)
Ending balance	2,751,174
U.S. Facilities [Member] | Operating Segment [Member]
Goodwill:
Beginning balance	2,041,795
Purchase price allocation and other	797
Ending balance	2,042,592
U.K. Facilities [Member] | Operating Segment [Member]
Goodwill:
Beginning balance	639,393
Increase from 2017 acquisition	15,302
Foreign currency translation	60,770
Purchase price allocation and other	(6,883)
Ending balance	$ 708,582

Segment Information - Summary93

Segment Information - Summary of Financial Information by Operating Segment, Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets:
Assets	$ 6,424,502	$ 6,024,726
U.S. Facilities [Member] | Operating Segment [Member]
Assets:
Assets	3,567,126	3,382,167
U.K. Facilities [Member] | Operating Segment [Member]
Assets:
Assets	2,647,150	2,441,018
Corporate and Other [Member] | Corporate Reconciling Items and Eliminations [Member]
Assets:
Assets	$ 210,226	$ 201,541

Segment Information - Summary94

Segment Information - Summary of Financial Information by Operating Segment, Assets (Parenthetical) (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 3,048,130	$ 2,703,695
Operating Segment [Member] | U.S. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,200,000	1,000,000
Operating Segment [Member] | U.K. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,800,000	1,700,000
Corporate Reconciling Items and Eliminations [Member] | Corporate and Other [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 49,200	$ 27,100

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Employee benefit plan, Accumulated other comprehensive income (loss)	$ (4,100)	$ (7,400)	$ 2,600
Employee benefit plan, Accumulated other comprehensive income (loss) , Net	(4,500)	6,100	(1,700)
Defined Contribution Plan [Member] | 401(k) [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, employer discretionary contribution amount	200	100	$ 100
Pension Plan [Member] | Partnership in Care Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Pension liability under defined benefit pension plan	67,288	64,162
Pension Plan [Member] | Partnership in Care Benefits Plan [Member] | Other Liabilities [Member]
Defined Benefit Plan Disclosure [Line Items]
Pension liability under defined benefit pension plan	$ 8,800	$ 10,700

Employee Benefit Plans - Summar

Employee Benefit Plans - Summary of Funded Status (Unfunded Liability) of Partnerships in Care Pension Plan Based Upon Actuarial Valuations (Detail) - Pension Plan [Member] - Partnership in Care Benefits Plan [Member] - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 67,288	$ 64,162
Fair value of plan assets	58,493	53,462
Unfunded liability	$ 8,795	$ 10,700	$ 2,821

Employee Benefit Plans - Summ97

Employee Benefit Plans - Summary of Changes in Partnerships in Care Pension Plan Net Pension Liability (Detail) - Pension Plan [Member] - Partnership in Care Benefits Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Net pension liability at beginning of period	$ 10,700	$ 2,821
Employer contributions	(809)	(740)
Net pension expense (benefit)	426	339
Pension liability adjustment	(2,544)	8,781
Foreign currency translation gain (loss)	1,022	(501)
Net pension liability at end of period	$ 8,795	$ 10,700

Employee Benefit Plans - Summ98

Employee Benefit Plans - Summary of Assumptions Used to Determine Plan Benefit Obligation (Detail) - Pension Plan [Member] - Partnership in Care Benefits Plan [Member]	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.50%	2.70%
Compensation increase rate	2.30%	2.40%

Employee Benefit Plans - Summ99

Employee Benefit Plans - Summary of Components of Net Pension Plan Expense (Detail) - Pension Plan [Member] - Partnership in Care Benefits Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Interest cost on projected benefit obligation	$ 1,738	$ 1,964
Expected return on assets	(1,312)	(1,625)
Total pension plan expense (benefit)	$ 426	$ 339

Employee Benefit Plans - Sum100

Employee Benefit Plans - Summary of Assumptions Used to Determine Net Periodic Pension Plan Expense (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Retirement Benefits [Abstract]
Discount rate	2.50%	2.70%
Expected long-term rate of return on plan assets	2.50%	2.70%

Employee Benefit Plans - Schedu

Employee Benefit Plans - Schedule of Weighted-Average Asset Allocation by Asset Category in Partnerships in Care Pension Plan (Detail) - Pension Plan [Member] - Partnership in Care Benefits Plan [Member]	Dec. 31, 2017	Dec. 31, 2016
Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	0.70%	1.50%
Foreign Government Debt Securities [Member] | United Kingdom [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	19.00%	14.50%
Annuity Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	38.60%	41.60%
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	29.40%	26.30%
Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	9.90%	12.10%
Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	2.40%	4.00%

Other Comprehensive Loss - Comp

Other Comprehensive Loss - Components Of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 2,167,724	$ 1,683,028	$ 880,965
Foreign currency translation gain (loss)	207,341	(477,772)	(40,103)
Gain (Loss) on derivative instruments, net of tax of $29.1 million and $(22.9) million respectively	(33,431)	40,598
Pension liability adjustment, net of tax of $0.4 million	1,542	(7,749)	3,826
Balance	2,572,871	2,167,724	1,683,028
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(584,081)	(106,309)	(66,206)
Foreign currency translation gain (loss)	207,341	(477,772)	(40,103)
Balance	(376,740)	(584,081)	(106,309)
Change in Fair Value of Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	40,598
Gain (Loss) on derivative instruments, net of tax of $29.1 million and $(22.9) million respectively	(33,431)	40,598
Balance	7,167	40,598
Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(6,087)	1,662	(2,164)
Pension liability adjustment, net of tax of $0.4 million	1,542	(7,749)	3,826
Balance	(4,545)	(6,087)	1,662
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(549,570)	(104,647)	(68,370)
Balance	$ (374,118)	$ (549,570)	$ (104,647)

Other Comprehensive Loss - C103

Other Comprehensive Loss - Components Of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Gain (Loss) on derivative instruments, tax	$ (22.9)	$ 29.1	$ 0
Pension liability adjustment, tax	$ 0.4	$ (1.3)	$ 0.9

Quarterly Information (Unaud104

Quarterly Information (Unaudited) - Schedule of Quarterly Financial Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Revenue	$ 724,512	$ 716,714	$ 715,896	$ 679,194	$ 702,888	$ 734,665	$ 756,548	$ 616,813	$ 2,877,234	$ 2,852,823	$ 1,829,619
Income from continuing operations before income taxes	60,639	61,459	66,216	48,484	42,438	(115,814)	73,852	32,479	236,798	32,955	164,753
Net income attributable to Acadia Healthcare Company, Inc. stockholders	$ 69,629	$ 45,618	$ 49,630	$ 34,958	$ 41,818	$ (117,808)	$ 56,445	$ 25,688	$ 199,835	$ 6,143	$ 112,554
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$ 0.80	$ 0.52	$ 0.57	$ 0.40	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	$ 2.30	$ 0.07	$ 1.65
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$ 0.80	$ 0.52	$ 0.57	$ 0.40	$ 0.48	$ (1.36)	$ 0.65	$ 0.31	$ 2.30	$ 0.07	$ 1.64

Quarterly Information (Unaud105

Quarterly Information (Unaudited) - Schedule of Quarterly Financial Information (Parenthetical) (Detail) - USD ($) $ in Thousands	Nov. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information [Line Items]
One-time tax benefits on enactment of Tax Act		$ 20,200			$ 31,372	$ 28,647	$ 43,613
Loss on divestiture						(178,809)
Debt extinguishment costs					$ (810)	(4,253)	$ (10,818)
U.K. Disposal Group [Member]
Quarterly Financial Information [Line Items]
Loss on divestiture	$ 175,000			$ 174,700		$ 175,000
Divestiture [Member]
Quarterly Financial Information [Line Items]
Loss on divestiture			$ 4,000
Tranche B-2 Repricing Amendment [Member]
Quarterly Financial Information [Line Items]
Debt extinguishment costs				3,400
Debt extinguishment costs, net of taxes				$ 142,000
Refinancing Amendment [Member]
Quarterly Financial Information [Line Items]
Debt extinguishment costs			800
Debt extinguishment costs, net of taxes			$ 3,100

Financial Information for th106

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Dec. 31, 2017	Dec. 31, 2016	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%

Financial Information for th107

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 67,290	$ 57,063	$ 11,215	$ 94,040
Accounts receivable, net	296,925	263,327
Other current assets	107,335	107,537
Total current assets	471,550	427,927
Property and equipment, net	3,048,130	2,703,695
Goodwill	2,751,174	2,681,188
Intangible assets, net	87,348	83,310
Deferred tax assets - noncurrent	3,731	3,780
Derivative instruments	12,997	73,509
Other assets	49,572	51,317
Total assets	6,424,502	6,024,726
Current liabilities:
Current portion of long-term debt	34,830	34,805
Accounts payable	102,299	80,034
Accrued salaries and benefits	99,047	105,068
Other accrued liabilities	141,213	122,958
Total current liabilities	377,389	342,865
Long-term debt	3,205,058	3,253,004
Deferred tax liabilities - noncurrent	80,333	78,520
Other liabilities	166,434	164,859
Total liabilities	3,829,214	3,839,248
Redeemable noncontrolling interests	22,417	17,754
Total equity	2,572,871	2,167,724	1,683,028	880,965
Total liabilities and equity	6,424,502	6,024,726
Consolidating Adjustments [Member]
Current assets:
Deferred tax assets - noncurrent	(2,370)	(14,348)
Investment in subsidiaries	(5,429,386)	(4,885,865)
Other assets	(379,008)	(489,646)
Total assets	(5,810,764)	(5,389,859)
Current liabilities:
Long-term debt	(379,008)	(489,646)
Deferred tax liabilities - noncurrent	(2,370)	(14,348)
Total liabilities	(381,378)	(503,994)
Total equity	(5,429,386)	(4,885,865)
Total liabilities and equity	(5,810,764)	(5,389,859)
Parent [Member]
Current assets:
Deferred tax assets - noncurrent	2,370	13,522
Derivative instruments	12,997	73,509
Investment in subsidiaries	5,429,386	4,885,865
Other assets	381,913	493,294
Total assets	5,826,666	5,466,190
Current liabilities:
Current portion of long-term debt	34,550	34,550
Other accrued liabilities	36,196	33,616
Total current liabilities	70,746	68,166
Long-term debt	3,183,049	3,230,300
Total liabilities	3,253,795	3,298,466
Total equity	2,572,871	2,167,724
Total liabilities and equity	5,826,666	5,466,190
Combined Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	46,860	15,681	1,987	76,685
Accounts receivable, net	230,890	209,124
Other current assets	85,746	61,724
Total current assets	363,496	286,529
Property and equipment, net	1,086,802	940,880
Goodwill	1,936,057	1,935,260
Intangible assets, net	57,628	56,676
Other assets	38,860	40,480
Total assets	3,482,843	3,259,825
Current liabilities:
Accounts payable	70,767	49,205
Accrued salaries and benefits	69,057	72,835
Other accrued liabilities	27,676	24,375
Total current liabilities	167,500	146,415
Deferred tax liabilities - noncurrent	27,975	40,574
Other liabilities	103,112	101,938
Total liabilities	298,587	288,927
Total equity	3,184,256	2,970,898
Total liabilities and equity	3,482,843	3,259,825
Combined Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	20,430	41,382	$ 9,228	$ 17,355
Accounts receivable, net	66,035	54,203
Other current assets	21,589	45,813
Total current assets	108,054	141,398
Property and equipment, net	1,961,328	1,762,815
Goodwill	815,117	745,928
Intangible assets, net	29,720	26,634
Deferred tax assets - noncurrent	3,731	4,606
Other assets	7,807	7,189
Total assets	2,925,757	2,688,570
Current liabilities:
Current portion of long-term debt	280	255
Accounts payable	31,532	30,829
Accrued salaries and benefits	29,990	32,233
Other accrued liabilities	77,341	64,967
Total current liabilities	139,143	128,284
Long-term debt	401,017	512,350
Deferred tax liabilities - noncurrent	54,728	52,294
Other liabilities	63,322	62,921
Total liabilities	658,210	755,849
Redeemable noncontrolling interests	22,417	17,754
Total equity	2,245,130	1,914,967
Total liabilities and equity	$ 2,925,757	$ 2,688,570

Financial Information for th108

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	$ 724,512	$ 716,714	$ 715,896	$ 679,194	$ 702,888	$ 734,665	$ 756,548	$ 616,813	$ 2,877,234	$ 2,852,823	$ 1,829,619
Provision for doubtful accounts									(40,918)	(41,909)	(35,127)
Revenue									2,836,316	2,810,914	1,794,492
Salaries, wages and benefits									1,536,160	1,541,854	973,732
Professional fees									196,223	185,486	116,463
Supplies									114,439	117,425	80,663
Rents and leases									76,775	73,348	32,528
Other operating expenses									331,827	312,556	206,746
Depreciation and amortization									143,010	135,103	63,550
Interest expense, net									176,007	181,325	106,742
Debt extinguishment costs									810	4,253	10,818
Loss on divestiture										178,809
Loss (gain) on foreign currency derivatives										(523)	1,926
Transaction-related expenses									24,267	48,323	36,571
Total expenses									2,599,518	2,777,959	1,629,739
(Loss) income from continuing operations before income taxes	60,639	61,459	66,216	48,484	42,438	(115,814)	73,852	32,479	236,798	32,955	164,753
(Benefit from) provision for income taxes									37,209	28,779	53,388
Income (loss) from continuing operations									199,589	4,176	111,365
Income from discontinued operations, net of income taxes											111
Net income (loss)									199,589	4,176	111,476
Net income (loss) attributable to noncontrolling interests									246	1,967	1,078
Net income attributable to Acadia Healthcare Company, Inc.	$ 69,629	$ 45,618	$ 49,630	$ 34,958	$ 41,818	$ (117,808)	$ 56,445	$ 25,688	199,835	6,143	112,554
Other comprehensive income:
Foreign currency translation gain (loss)									207,341	(477,772)	(40,103)
(Loss) gain on derivative instruments									(33,431)	40,598
Pension liability adjustment, net of tax of $0.9 million, $(1.3) million and $0.3 million, respectively									1,542	(7,749)	3,826
Other comprehensive income									175,452	(444,923)	(36,277)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.									375,287	(438,780)	76,277
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in earnings of subsidiaries									(259,282)	(65,560)	(176,178)
Income (loss) from continuing operations									(259,282)	(65,560)	(176,178)
Net income (loss)									(259,282)	(65,560)	(176,178)
Net income attributable to Acadia Healthcare Company, Inc.									(259,282)	(65,560)	(176,178)
Other comprehensive income:
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.									(259,282)	(65,560)	(176,178)
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Salaries, wages and benefits									23,467	28,345	20,472
Interest expense, net									61,872	50,921	68,533
Debt extinguishment costs									810	4,253	10,818
Loss (gain) on foreign currency derivatives										(523)	1,926
Total expenses									86,149	82,996	101,749
(Loss) income from continuing operations before income taxes									(86,149)	(82,996)	(101,749)
Equity in earnings of subsidiaries									259,282	65,560	176,178
(Benefit from) provision for income taxes									(26,456)	(21,612)	(37,047)
Income (loss) from continuing operations									199,589	4,176	111,476
Net income (loss)									199,589	4,176	111,476
Net income attributable to Acadia Healthcare Company, Inc.									199,589	4,176	111,476
Other comprehensive income:
(Loss) gain on derivative instruments									(33,431)	40,598
Other comprehensive income									(33,431)	40,598
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.									166,158	44,774	111,476
Combined Subsidiary Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts									1,746,656	1,662,734	1,415,016
Provision for doubtful accounts									(35,636)	(38,349)	(32,614)
Revenue									1,711,020	1,624,385	1,382,402
Salaries, wages and benefits									902,180	865,104	726,215
Professional fees									93,991	89,062	83,422
Supplies									75,248	76,246	65,077
Rents and leases									33,365	34,540	29,094
Other operating expenses									217,900	206,308	170,018
Depreciation and amortization									66,482	58,018	41,768
Interest expense, net									81,274	75,848	17,476
Loss on divestiture										778
Transaction-related expenses									11,236	32,173	24,914
Total expenses									1,481,676	1,438,077	1,157,984
(Loss) income from continuing operations before income taxes									229,344	186,308	224,418
(Benefit from) provision for income taxes									69,882	68,335	85,765
Income (loss) from continuing operations									159,462	117,973	138,653
Income from discontinued operations, net of income taxes											111
Net income (loss)									159,462	117,973	138,764
Net income attributable to Acadia Healthcare Company, Inc.									159,462	117,973	138,764
Other comprehensive income:
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.									159,462	117,973	138,764
Combined Non-Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts									1,130,578	1,190,089	414,603
Provision for doubtful accounts									(5,282)	(3,560)	(2,513)
Revenue									1,125,296	1,186,529	412,090
Salaries, wages and benefits									610,513	648,405	227,045
Professional fees									102,232	96,424	33,041
Supplies									39,191	41,179	15,586
Rents and leases									43,410	38,808	3,434
Other operating expenses									113,927	106,248	36,728
Depreciation and amortization									76,528	77,085	21,782
Interest expense, net									32,861	54,556	20,733
Loss on divestiture										178,031
Transaction-related expenses									13,031	16,150	11,657
Total expenses									1,031,693	1,256,886	370,006
(Loss) income from continuing operations before income taxes									93,603	(70,357)	42,084
(Benefit from) provision for income taxes									(6,217)	(17,944)	4,670
Income (loss) from continuing operations									99,820	(52,413)	37,414
Net income (loss)									99,820	(52,413)	37,414
Net income (loss) attributable to noncontrolling interests									246	1,967	1,078
Net income attributable to Acadia Healthcare Company, Inc.									100,066	(50,446)	38,492
Other comprehensive income:
Foreign currency translation gain (loss)									207,341	(477,772)	(40,103)
Pension liability adjustment, net of tax of $0.9 million, $(1.3) million and $0.3 million, respectively									1,542	(7,749)	3,826
Other comprehensive income									208,883	(485,521)	(36,277)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.									$ 308,949	$ (535,967)	$ 2,215

Financial Information for th109

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Cash Flows (Detail) $ in Thousands, £ in Millions	Nov. 30, 2016GBP (£)	Jan. 12, 2016USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Operating activities:
Net income (loss)				$ 199,589	$ 4,176	$ 111,476
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization				143,010	135,103	63,550
Amortization of debt issuance costs				9,855	10,324	6,709
Equity-based compensation expense				23,467	28,345	20,472
Deferred income tax (benefit) expense			$ 20,200	31,372	28,647	43,613
Loss from discontinued operations, net of taxes						(111)
Debt extinguishment costs				810	4,253	10,818
Loss on divestiture					178,809
(Gain) loss on foreign currency derivatives					(523)	1,926
Other				11,412	4,715	1,615
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net				(28,570)	(15,718)	(24,954)
Other current assets				20,808	(20,648)	(2,717)
Other assets				(3,176)	(4,354)	(8,021)
Accounts payable and other accrued liabilities				(10,113)	22,693	6,868
Accrued salaries and benefits				(8,988)	(8,572)	1,658
Other liabilities				11,794	4,484	9,236
Net cash (used in) provided by continuing operating activities				401,270	371,734	242,138
Net cash provided by discontinued operating activities				(1,693)	(10,256)	(1,735)
Net cash (used in) provided by operating activities				399,577	361,478	240,403
Investing activities:
Cash paid for acquisitions, net of cash acquired				(18,191)	(683,455)	(574,777)
Cash paid for capital expenditures				(274,177)	(307,472)	(276,047)
Cash paid for real estate acquisitions				(41,057)	(40,757)	(26,622)
Settlement of foreign currency derivatives					523	(1,926)
Cash received for divestiture	£ 320				373,266
Other				(3,101)	(2,470)	(5,099)
Net cash used in investing activities				(336,526)	(660,365)	(884,471)
Financing activities:
Borrowings on long-term debt					1,480,000	1,150,000
Borrowings on revolving credit facility					179,000	468,000
Principal payments on revolving credit facility					(337,000)	(310,000)
Principal payments on long-term debt				(34,805)	(49,941)	(31,965)
Repayment of assumed debt					(1,348,389)	(904,467)
Repayment of long-term debt				(22,500)	(200,594)	(97,500)
Payment of debt issuance costs					(36,649)	(26,421)
Payment of premium on senior notes						(7,480)
Issuance of common stock, net		$ 685,000			685,097	331,308
Common stock withheld for minimum statutory taxes, net				(3,455)	(8,846)	(7,762)
Excess tax benefit from equity awards						309
Other				686	(3,837)	(420)
Net cash provided by (used in) financing activities				(60,074)	358,841	563,602
Effect of exchange rate changes on cash				7,250	(14,106)	(2,359)
Net (decrease) increase in cash and cash equivalents				10,227	45,848	(82,825)
Cash and cash equivalents at beginning of the period				57,063	11,215	94,040
Cash and cash equivalents at end of the period			67,290	67,290	57,063	11,215
Consolidating Adjustments [Member]
Operating activities:
Net income (loss)				(259,282)	(65,560)	(176,178)
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries				259,282	65,560	176,178
Change in operating assets and liabilities, net of effect of acquisitions:
Other assets				(24,549)	3,109	1,100
Net cash (used in) provided by continuing operating activities				(24,549)	3,109	1,100
Net cash (used in) provided by operating activities				(24,549)	3,109	1,100
Financing activities:
Principal payments on long-term debt				24,549	296,109	1,315
Cash (used in) provided by intercompany activity					(299,218)	(2,415)
Net cash provided by (used in) financing activities				24,549	(3,109)	(1,100)
Parent [Member]
Operating activities:
Net income (loss)				199,589	4,176	111,476
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries				(259,282)	(65,560)	(176,178)
Amortization of debt issuance costs				10,270	10,751	7,147
Equity-based compensation expense				23,467	28,345	20,472
Deferred income tax (benefit) expense				1,236	(2,172)	617
Debt extinguishment costs				810	4,253	10,818
(Gain) loss on foreign currency derivatives					(523)	1,926
Other				4,189
Change in operating assets and liabilities, net of effect of acquisitions:
Other assets				24,549	(3,109)	(1,100)
Net cash (used in) provided by continuing operating activities				4,828	(23,839)	(24,822)
Net cash (used in) provided by operating activities				4,828	(23,839)	(24,822)
Investing activities:
Cash received for divestiture					370,000
Net cash used in investing activities					370,000
Financing activities:
Borrowings on long-term debt					1,480,000	1,150,000
Borrowings on revolving credit facility					179,000	468,000
Principal payments on revolving credit facility					(337,000)	(310,000)
Principal payments on long-term debt				(34,550)	(49,706)	(31,965)
Repayment of assumed debt					(1,348,389)	(904,467)
Repayment of long-term debt				(22,500)	(200,594)	(97,500)
Payment of debt issuance costs					(36,649)	(26,421)
Payment of premium on senior notes						(7,480)
Issuance of common stock, net					685,097	331,308
Common stock withheld for minimum statutory taxes, net				(3,455)	(8,846)	(7,762)
Excess tax benefit from equity awards						309
Other				(539)	(1,149)
Cash (used in) provided by intercompany activity				56,216	(707,925)	(539,200)
Net cash provided by (used in) financing activities				(4,828)	(346,161)	24,822
Combined Subsidiary Guarantors [Member]
Operating activities:
Net income (loss)				159,462	117,973	138,764
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization				66,482	58,018	41,768
Deferred income tax (benefit) expense				28,882	50,611	42,246
Loss from discontinued operations, net of taxes						(111)
Loss on divestiture					778
Other				2,498	4,022	1,582
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net				(21,791)	(24,017)	(18,632)
Other current assets				(6,429)	(3,138)	(1,152)
Other assets				(3,277)	(4,048)	(8,567)
Accounts payable and other accrued liabilities				4,909	(45,552)	(7,583)
Accrued salaries and benefits				(3,974)	3,844	312
Other liabilities				8,794	4,050	9,350
Net cash (used in) provided by continuing operating activities				235,556	162,541	197,977
Net cash provided by discontinued operating activities				(1,693)	(10,256)	(1,735)
Net cash (used in) provided by operating activities				233,863	152,285	196,242
Investing activities:
Cash paid for acquisitions, net of cash acquired					(103,359)	(254,848)
Cash paid for capital expenditures				(161,312)	(177,593)	(172,329)
Cash paid for real estate acquisitions				(37,047)	(28,956)	(25,293)
Settlement of foreign currency derivatives					523	(1,926)
Cash received for divestiture					7,859
Other				(7,944)	(1,573)	(5,099)
Net cash used in investing activities				(206,303)	(303,099)	(459,495)
Financing activities:
Principal payments on long-term debt				(14,250)	(293,000)
Other				1,225	(2,688)	(420)
Cash (used in) provided by intercompany activity				16,644	460,196	191,334
Net cash provided by (used in) financing activities				3,619	164,508	190,914
Effect of exchange rate changes on cash						(2,359)
Net (decrease) increase in cash and cash equivalents				31,179	13,694	(74,698)
Cash and cash equivalents at beginning of the period				15,681	1,987	76,685
Cash and cash equivalents at end of the period			46,860	46,860	15,681	1,987
Combined Non-Guarantors [Member]
Operating activities:
Net income (loss)				99,820	(52,413)	37,414
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization				76,528	77,085	21,782
Amortization of debt issuance costs				(415)	(427)	(438)
Deferred income tax (benefit) expense				1,254	(19,792)	750
Loss on divestiture					178,031
Other				4,725	693	33
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net				(6,779)	8,299	(6,322)
Other current assets				27,237	(17,510)	(1,565)
Other assets				101	(306)	546
Accounts payable and other accrued liabilities				(15,022)	68,245	14,451
Accrued salaries and benefits				(5,014)	(12,416)	1,346
Other liabilities				3,000	434	(114)
Net cash (used in) provided by continuing operating activities				185,435	229,923	67,883
Net cash (used in) provided by operating activities				185,435	229,923	67,883
Investing activities:
Cash paid for acquisitions, net of cash acquired				(18,191)	(580,096)	(319,929)
Cash paid for capital expenditures				(112,865)	(129,879)	(103,718)
Cash paid for real estate acquisitions				(4,010)	(11,801)	(1,329)
Cash received for divestiture					(4,593)
Other				4,843	(897)
Net cash used in investing activities				(130,223)	(727,266)	(424,976)
Financing activities:
Principal payments on long-term debt				(10,554)	(3,344)	(1,315)
Cash (used in) provided by intercompany activity				(72,860)	546,947	350,281
Net cash provided by (used in) financing activities				(83,414)	543,603	348,966
Effect of exchange rate changes on cash				7,250	(14,106)
Net (decrease) increase in cash and cash equivalents				(20,952)	32,154	(8,127)
Cash and cash equivalents at beginning of the period				41,382	9,228	17,355
Cash and cash equivalents at end of the period			$ 20,430	$ 20,430	$ 41,382	$ 9,228